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 Understanding behavioral predictors of individual differences in opioid addiction 
vulnerability could provide critical insights into the mechanisms underlying opioid 
addiction and could lead to more effective treatments. However, very few behavioral 
predictors of individual differences in opioid self-administration (SA), a key preclinical 
model of opioid addiction, have been established. The goal of this dissertation was to 
evaluate several potential behavioral predictors of individual differences in morphine SA 
in rats, and to establish novel methodologies for studying opioid addiction vulnerability 
using the SA paradigm. Study 1 showed that spontaneous locomotor activity in a novel 
environment, an animal model of sensation-seeking that predicts SA of several drugs of 
abuse (e.g., stimulants), did not predict individual differences in morphine SA. Study 2 
found that greater severity of anhedonia-like behavior during withdrawal from acute 
morphine exposure (withdrawal-induced anhedonia, WIA) predicted subsequent lower 
acquisition, demand, and reinstatement of morphine SA. Study 3 showed the feasibility 
of using regularized factor analysis on morphine SA measures, and revealed that a 
common latent factor underlies four separate measures of morphine SA. Additionally, 
while acquisition, demand and morphine-induced reinstatement associated closely with 
the common latent Addiction factor, stress-induced reinstatement did not. Overall, these 
studies extended the opioid individual differences literature by establishing WIA as one 
of the first behavioral predictors of opioid SA, and also expanded the range of analytical 
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Chapter 1: Introduction 
 Characterizing personality and behavioral traits contributing to individual differences 
in vulnerability to addiction and other psychiatric disorders is essential for developing a greater 
understanding of underlying genetic and molecular mechanisms, as well as more effective 
preventions and treatments.  Given substantial individual variability in its vulnerability and 
severity (American Psychiatric Association, 2013; Belin et al., 2016; Vowles et al., 2015), 
opioid addiction is a prime example of a disorder that could benefit from a clearer 
understanding of these mechanisms.  Despite the enormous toll of opioid addiction on public 
health, most behavioral predictors of vulnerability to addiction established with other drugs of 
abuse are less well established when it comes to opioids, both in humans and animal models. 
Given differences in the neurobiological effects (e.g. receptor pharmacology and drug-induced 
synaptic and structural plasticity) between different classes of drugs of abuse (Badiani et al., 
2011; Ettenberg et al., 1982; Pettit et al.,1984), it is important to characterize vulnerability 
factors that are specific to opioid addiction.  
 Preclinical studies provide a number of advantages over human studies for studying 
individual differences in opioid addiction vulnerability. First, animal behavioral studies allow 
examination of vulnerability factors in a controlled environment, thereby minimizing the 
number of extraneous variables (e.g., other mental disorders) that may confound findings. 
Second, researchers have control over subjects’ drug-exposure history, allowing for isolation 
of the factors uniquely associated with effects of opioids versus other drugs. Third, animal 
models allow experimental, as opposed to quasi-experimental or cross-sectional study designs, 
thereby shedding light on causal relationships between variables that could not be identified 





characterize neurobiological and genetic mechanisms underlying addiction vulnerability 
(Parker et al., 2014). 
 In preclinical research, various behavioral models have been developed in an effort to 
operationalize human personality traits implicated in addiction vulnerability (e.g., impulsivity, 
novelty-seeking, etc.)  The purpose of this review is to evaluate the utility of such measures in 
predicting opioid addiction vulnerability as measured using the self-administration (SA) 
paradigm in rats.  For several reasons, drug SA is often considered a model with an especially 
high degree of translational utility.  First, while other animal models of addiction (e.g., 
conditioned place preference, locomotor sensitization) involve experimenter-administered 
drug, the SA model involves volitional drug-taking, as occurs in human. Second, various SA 
measures capture different elements of human addictive behavior such as the initiation of drug 
use (acquisition), loss of control over drug use (escalation), and relapse (reinstatement) (Table 
1) (Belin et al., 2008; Grebenstein et al., 2013; McNamara et al., 2010; Leri et al., 2004; Sorge 
et al., 2005).  Moreover, the SA model has some degree of face and predictive validity in 
modeling opioid addition.  For example, there was a close correspondence between the abuse 
liability of 23 opioid-related drugs in the rat SA model and their positive subjective effects 
and/or abuse potential in humans (O’Connor et al., 2010). Therefore, despite the limitations in 
construct validity of any single animal model of human psychopathology (Geyer & Markou, 
2000), opioid SA is often considered an appropriate model for studying opioid addiction in 
animals.    
Our primary focus will be on studies of outbred rats, which have been most commonly used 





predictors (Parker et al., 2014). Studies of inbred or selectively bred strains will also be 
discussed to provide further insights on the relationships between certain behavioral predictors 
and opioid SA propensity.  We conclude that few reliable behavioral predictors of opioid SA 
have been identified.  We therefore propose several strategies for assessing and analyzing the 
relationship between predictor variables and the severity of opioid SA that may help uncover 
more robust behavioral phenotypes for elucidating the substrates of opioid addiction in people. 
Such approaches could also help improve the validity and sensitivity of the opioid SA model 
in general. 
Behavioral Predictors of Opioid Addiction Vulnerability 
 As described below, a number of traits have been evaluated as putative predictors of 
vulnerability to opioid SA in rats.  
Impulsivity 
 Impulsivity refers to the tendency to engage in premature and suboptimal behaviors 
(Bardo, 2013; Kurth-Nelson & Redish, 2010). Most facets of impulsivity can be categorized 
as forms of either impulsive action (difficulty inhibiting or controlling behavior), or impulsive 
choice (preference for small, immediate rewards over larger, delayed rewards) (Baldacchino 
et al., 2015; Swann et al., 2009).  
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Table 1. Measures of SA  
Stage of Addiction SA Model Operational Measure Example Study 
Initiation of drug use Acquisition Average number of 
infusions earned during 
first days of drug SA 
Belin et al., 2008; 
Nishida et a., 2016; 
Smith et al., 2015;  
Suto et al., 2001 







Breakpoint, or the highest 
fixed ratio at which the 
animal maintains 
responding for drug; 
Elasticity of demand or 
essential value 
Hodos, 1961;  
Katz, 1990;  
Richardson & 
Roberts, 1996; 
Grebenstein et al., 
2013; Stafford et al., 
2019 
Loss of control over 
drug use 
Escalation  Increase in number of 
infusions earned after 
duration of daily access to 
drug is extended 
Kitamura et al., 2006; 
Edwards & Koob, 
2013; Ahmed & 
Koob, 1999 




Reduction in drug SA 
when infusions are 
accompanied by aversive 




Belin et al., 2008 
Relapse to drug use 
following exposure to 
drug-associated 
environmental cues, 




Increase in drug-seeking 
(active lever pressing) 
following extinction of 
SA and exposure to drug-
associated cue stimuli, 
stress (e.g., foot shock), 
or non-contingent 
injection of previously 
self-administered drug 
Childress et al., 1993; 
Epstein et al., 2006; 
McNamara et al., 
2010; 
de Wit, 1996; 






Clinical findings  
 Higher impulsivity has been associated with a higher risk of opioid addiction in some 
clinical studies (Marino et al., 2013; Nielsen et al., 2012; Vest et al., 2016), while another 
found no relationship between impulsivity and heroin use (Ahn & Vassileva, 2016). These 
inconsistent findings may stem from a variety of factors including differences in the population 
studied, the measure or subscales of impulsivity evaluated (e.g., attentional versus motoric 
impulsivity), and/or history of opioid and other drug use. Additionally, high impulsivity could 
be a consequence of opioid exposure rather than a predisposing trait (Baldacchino et al., 2015).  
As such, the extent to which impulsivity predisposes an individual to opioid addiction is 
unclear.    
Preclinical findings 
 Preclinical studies have not found an association between trait impulsivity and opioid 
SA. Individual differences in impulsive action measured using the 5-choice serial reaction time 
task (5-CSRTT, see Table 2 for a description of this and other behavioral measures evaluated 
as predictors of opioid SA) did not predict subsequent acquisition, escalation, or cue-induced 
reinstatement of heroin SA (40 μg/100 μl) under a fixed ratio (FR) schedule of reinforcement 
in rats (McNamara et al., 2010). Similarly, there was no relationship between impulsive choice 
in a delayed reward procedure (see Table 2a) and several measures of heroin SA (100 
μg/kg/infusion; FR1, 2 and 4) in rats including acquisition, breakpoint during progressive ratio 
testing (i.e., reinforcing efficacy), or drug seeking during extinction or cue- or drug-induced 
reinstatement (Schippers et al., 2012). This contrasts with the positive relationships between 
impulsivity in 5-CSRTT and delayed-reward procedures and SA of other drugs of abuse such 





al., 2009). Nevertheless, when rats in the Schippers et al. (2012) study were tested on the 
delayed-reward task again after completion of heroin SA, those with a history of heroin SA 
showed increased impulsivity compared to baseline. Another study found no effects of 
experimenter-administered heroin on impulsivity (Harty et al., 2011). However, a more recent 
study found that experimenter-administered morphine increased short-term motor impulsivity 
in adolescent, young adult, and adult rats, and increased long-term motor impulsivity (i.e, 
following a 25 day drug-free period) in adolescents (Moazen et al., 2018).   
 Overall, these preclinical studies suggest that impulsive behavior may be an effect of 
opioid exposure rather than a preexisting vulnerability trait for addiction, as has been suggested 
in humans (Baldacchino et al. 2015). The findings of Moazen et al. (2018) further suggest that 
the effects of adolescent opioid exposure on impulsivity may be long-lasting. Such enduring 
effects could contribute to the difficulty in parsing cause from effect in human studies 
evaluating the role of impulsivity in opioid addiction vulnerability.  
Sensation seeking 
 Sensation seeking refers to the tendency to attain novel and intense experiences despite 
risks (Zuckerman, 1994). Sensation seeking has been associated with other addiction-related 
traits such as impulsivity (Hur & Bouchard,1997; Krueger et al., 2002), and there is some 
overlap in how these traits are defined (Ahn & Vassileva, 2016; Whiteside & Lynam, 2001).  
Clinical findings 
 Despite some human studies showing a positive relationship between sensation seeking 
and opioid addiction vulnerability (Franques et al., 2003; Kosten et al., 1994; Vest et al., 2016), 





al., 2012) or a negative relationship (Ahn & Vassileva, 2016). These inconsistencies may 
reflect the same general limitations of human studies described above.  
Preclinical findings  
 Two tests have been developed to model sensation seeking in rats. The first uses 
spontaneous locomotor activity in a novel environment as a measure of novelty seeking — a 
dimension of sensation seeking (Blanchard et al., 2009; Pawlak et al., 2008; Piazza et al., 1989). 
Higher locomotor activity reliably predicts greater SA of psychostimulants (e.g., cocaine, 
amphetamine), particularly in terms of acquisition (Piazza et al., 1989; Piazza et al., 2000). 
These findings are consistent with studies showing a positive relationship between sensation 
seeking and psychostimulant use in humans (Ahn & Vassileva, 2016; Nielsen et al., 2012). 
 Only limited data speak to the relationship between spontaneous locomotor activity and 
opioid SA vulnerability.  Inbred rat strains with higher locomotor activity also exhibited greater 
acquisition of morphine SA (1 mg/kg, FR 1) under certain conditions compared to other strains 
(Ambrosio et al., 1995). Studies 1 and 2 of this dissertation provide the first characterization 
of the relationship between locomotor activity and individual differences in opioid SA 
vulnerability in outbred rats  (see below).   
 Another model for sensation seeking in rats focuses on preference for novelty, 
measured using a choice task, rather than reactivity to novelty (Belin et al., 2008; Belin et al., 
2011; Belin & Deroche-Gamonet, 2012).  However, this factor has not been studied in the 
context of opioid SA vulnerability. Thus, the relationship between opioid SA vulnerability and 
sensation-seeking, measured using either spontaneous activity or novelty preference, has 







The self-medication hypothesis of addiction (Khantzian, 1987) posits that individuals 
experiencing greater anxiety are more likely to choose addictive drugs with anxiolytic 
properties, such as opioids (Khantzian, 1987; Markou et al.,1998). The fact that anxiety has 
been linked to opioid addiction vulnerability in humans is consistent with this hypothesis 
(Lejuez et al., 2008; Martins et al., 2012; Norton, 2001; Rogers et al., 2018). However, the 
experience of negative affect including anxiety is common during withdrawal from opioids 
and other drugs (Koob & LeMoal, 1997).  Therefore, as with other putative predictive traits, it 
is unclear whether anxiety is a predictor of opioid addiction vulnerability, a consequence of 
chronic opioid use, or both.  
Preclinical findings 
The relationship between anxiety and opioid addiction has not been well established in 
animal models. Rats categorized as showing High- versus Low-anxiety based on time spent in 
the open arms of an elevated plus-maze (EPM; see Table 2) did not differ in their subsequent 
escalation of heroin SA (40 μg/100 μl/infusion; FR1), and time spent on the open arms of the 
EPM did not correlate with heroin SA escalation (Dileen et al 2012). In contrast, anxiety-like 
behavior in rodents predicts individual differences in SA of drugs other than opioids, such as 
cocaine (Dilleen et al., 2012; Pelloux et al., 2009; Walker et al., 2009). The role of anxiety in 
individual differences in opioid SA has not yet been studied via measurement of additional 





anxiety disorders (e.g., conflict or defensive behavior, conditioned fear) (Blanchard et al., 1993; 
Shekhar et al., 2001). 
Stress Reactivity 
Clinical findings 
 Stress is associated with opioid use both mechanistically and epidemiologically. First, 
opioids suppress activity of the hypothalamo-pituitary-adrenal (HPA) axis (Goeders, 2007; 
Facchinetti et a., 1985; Kreek et al., 2005), whereas opioid withdrawal activates the HPA axis 
(Li et al., 2008). Second, post-traumatic stress disorder (PTSD) and opioid addiction share 
certain symptoms and are frequently comorbid (Fareed et al., 2013). The link between 
vulnerability to the effects of stress and to opioid addiction is further supported by clinical 
studies showing a positive relationship between stress reactivity and opioid use (Back et al., 
2015; McHugh et al., 2016). For example, patients with prescription opioid dependence 
exhibited higher reactivity than controls to acute social stress (Back et al., 2015).  
Preclinical findings 
 Numerous preclinical studies have found that exposure to stressors can elicit or 
exacerbate opioid addiction-related behavior (e.g., Shaham & Stewart, 1994; Shaham, 1993). 
However, in the only study to evaluate stress reactivity as a predictor of opioid addiction 
vulnerability (Stafford et al., 2019), higher behavioral (open-field activity, forced swim test) 
and hormonal (corticosterone) reactivity to intermittent swim stress were predictive of higher 
reinforcing efficacy for heroin SA (0.05 mg/kg/infusion) in rats measured using a behavioral 
economic approach (see below for further discussion of behavioral economics). The 





may underlie this positive relationship (Koob, 2013; Kreek et al., 2005; Piazza & Le Moal, 
1996).  
Sensitivity to Acute Drug Effects 
Clinical findings  
 Sensitivity to the initial acute effects of drugs (e.g., euphoria, aversion) has long been 
recognized as a key predictor of addiction vulnerability to drugs other than opioids (DiFranza 
et al., 2007; O'Loughlin et al., 2003; Schuckit et al., 2004). For instance, sensitivity to the 
relaxing effects of tobacco during first exposure is a robust predictor of subsequent nicotine 
addiction (DiFranza et al. 2007). However, these relationships have not yet been examined in 
clinical studies on opioids.  
Preclinical findings  
Acute opioid effects 
 Only one preclinical study has evaluated the relationship between the acute effects of 
opioids and subsequent opioid SA. That study found that rats with lower sensitivity to the 
antinociceptive effects of morphine subsequently exhibited greater acquisition of morphine SA 
at a unit dose of 0.5 mg/kg/infusion under a FR 1 schedule of reinforcement (Nishida et al., 
2016).  This suggests that reduced sensitivity to the initial analgesic effect of opioids may 
predict greater opioid addiction vulnerability.  
Withdrawal effects 
 In addition to acute effects, opioid injections can also result in opioid withdrawal in 
both humans and animals. These withdrawal effects, characterized by negative affective 





only a single opioid exposure (“acute” dependence) (Harris & Gewirtz, 2004; Schulteis et al., 
2004) and often become more severe with repeated drug exposures (Engelmann et al., 2009; 
Harris et al., 2004; Schulteis et al., 2004). Avoidance of severe withdrawal effects following 
prolonged drug exposure may serve as a key motivational force driving compulsive drug-
taking (Koob & Le Moal 1997). In contrast, it has been proposed that greater sensitivity to the 
aversive effects of withdrawal may be a protective trait against addiction to opioids and other 
drugs (Carroll et al., 2008; Dess et al., 2005; Holtz et al., 2015; O'Dell et al., 2006; O'Dell, 
2009). Moreover, anhedonia during opioid withdrawal could potentially reduce the motivation 
for reward-seeking (Wise, 2004).  Consistent with these views, saccharin-preferring rats, which 
exhibit greater SA of opioids and other drugs compared to saccharin non-preferring rats 
(Carroll et al., 2002), exhibit lower anhedonia during withdrawal from acute morphine 
injections as measured by increases in intracranial self-stimulation (ICSS) thresholds (i.e., 
withdrawal-induced anhedonia, WIA). Study 2 of this dissertation evaluates the relationship 
between WIA and opioid addiction vulnerability in outbred rats (see below).  
 Contrary to findings using WIA, previous studies have found that saccharin-preferring 
(i.e., addiction-vulnerable) rats display higher anxiety during morphine withdrawal compared 
to saccharin non-preferring rats as measured by potentiated acoustic startle responding (Radke 
et al., 2013; Table 2b). In addition, only the saccharin-preferring rats developed a morphine 
withdrawal-induced conditioned place aversion (Radke et al., 2013). Together, these findings 
suggest that early-stage negative affective withdrawal signs predict opioid addiction 
vulnerability, although the direction of the relationship depends on the withdrawal sign 





not be measured in established drug users to predict treatment efficacy, their further 
investigation in animal models may be valuable in identifying genetic and neurobiological 
mechanisms underlying vulnerability to opioid addiction.  
Conclusion 
 Evidence for the relationship between specific behavioral indices and opioid addiction 
vulnerability is mixed in human studies, and sparse in preclinical studies. With the possible 
exception of sensitivity to agonist/withdrawal effects and stress reactivity, none of the 
aforementioned behavioral traits reliably predict opioid SA in rats.  Furthermore, most of the 
studies described above used only a single opioid SA unit dose and only one schedule of 
reinforcement (typically FR 1). These limitations, along with the fact that most of these 
behavioral phenotypes were exclusively examined in male rats, may limit the generalizability 
of these findings. 
Translation of Preclinical Research 
 The fact that behavioral traits associated with addiction to other drugs of abuse (e.g., 
psychostimulants) have not reliably predicted opioid SA in preclinical studies raises the 
possibility that unique behavioral phenotypes, such as those associated with opioid exposure 
(e.g., WIA, see above), predict individual differences in opioid SA.  It is also possible that 
other factors implicated in individual differences in vulnerability to SA of other drugs, such as 
incentive salience (i.e., the tendency to attribute incentive value to drug-associated cues), could 
prove to be stronger predictors of opioid SA (Beckmann et al., 2011; Flagel et al., 2009). 
Alternatively, the issue could be one not of searching for additional measures but of refining  
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Table 2a. Measures of behavioral traits as predictors of opioid SA vulnerability 
  
Predictor Behavioral Model Description Study on Opioids Conclusion 
Impulsivity 5-Choice Serial Reaction 
Time Task (5-CSRTT) 
Response to light signal to 
obtain food after an inter-
trial interval. Premature 
responses are punished 
McNamara et al., 2010 
 
No difference between 
high-and low-impulsivity 
rats in heroin SA 
Delayed Reward Training Choice between small, 
immediate reward or 
delayed, bigger reward 
Schippers et al., 2012 No difference between 
high- and low-impulsivity 
rats in heroin SA. Heroin 
SA increased impulsive 
responses  
Sensation-seeking Spontaneous Locomotor 
Activity 
Amount of exploratory 
activity in a novel open-
field chamber 
Ambrosio et al., 1995 Inbred rat strains with 
higher activity levels 
showed greater morphine 
SA  
Anxiety Elevated Plus Maze 
(EPM) 
Amount of time spent on 
the open arms (no walls) 
of the maze   
Dilleen et al., 2012 No difference between 
high-and low-anxiety rats 
in heroin SA 
Stress reactivity Forced Swim Test (FST) Number of attempts to 
climb out of the testing 
container 
Stafford et al., 2019 Climbing behavior 
positively predicted 
subsequent demand for 
heroin SA  
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Hot Plate Test (Analgesic 
Effect) 
Nociception after acute 
opioid injection 
Nishida et al., 2016 Lower morphine-induced 
antinociception predicted 
greater morphine SA 





Lowest electrical brain 
stimulation intensity that 
maintains operant 
responding 
Holtz et al., 2015 Saccharin-preferring rats 





Acoustic startle response 
during withdrawal 
Radke et al., 2013 Saccharin-preferring rats 




Amount of time spent in 
an environment associated 
with withdrawal  
Radke et al., 2013 Only saccharin-preferring 
rats develop CPA to 





existing ones. That is, our metrics for measuring addiction vulnerability using opioid SA, 
and our means of statistically evaluating their relationship to specific vulnerability factors, 
may underestimate those factors’ predictive value. We propose that employing one or more 
novel approaches to behavioral measurement and statistical analysis, some of which have 
already shown their worth in human studies, may enable us to establish relationships 
between predictors and outcomes of opioid SA with greater construct and face validity 
(Geyer & Markou, 1995; Markou et al. 2009; Smith, 2020).  These approaches may 
ultimately also prove beneficial in furthering our understanding of individual differences 
in addiction to other drugs of abuse, such as stimulants.  
Further Refining the SA Paradigm 
Behavioral Economics 
 Behavioral economics quantifies the extent to which consumption of a reinforcer 
(e.g., drug) is maintained following increases in its “unit price.” In drug SA models, unit 
price is operationalized as the cost-benefit ratio of response requirement and unit dose 
(Bickel et al., 2000; Hursh, 1991; Hursh & Silberberg, 2008). A more rapid decrease in 
consumption following increases in unit price (lower demand) indicates lower abuse 
liability, while a slower decrease (higher demand) indicates higher abuse liability. 
Behavioral economics provides an operationalized and quantifiable measure of 
reinforcement efficacy that can be used in humans and animals, and has been useful for 
studying individual differences in demand for numerous addictive drugs (e.g., nicotine) in 
both species (Diergaarde et al., 2008; Grebenstein et al., 2013; Chase et al., 2013; Hursh & 





 A growing body of clinical and preclinical evidence supports the utility of 
behavioral economics in the study of opioid addiction. For instance, greater demand 
predicted poorer treatment outcomes for prescription opioid dependence (Worley et al., 
2015). Additionally, an exponential demand function closely approximated opioid demand 
in current and previous opioid users (Strickland et al., 2019), as well as in animals (Stafford 
et al., 2019). A recent preclinical studyexamined the relationships between stress reactivity 
and demand, demonstrating the feasibility and utility of this analytical approach in 
preclinical opioid addiction research (Stafford et al., 2019). Since most rodent opioid 
addiction measures are not directly comparable to measures used in humans, behavioral 
economics could prove to be a powerful translational tool (Bentzley et al, 2013).  
Alternative Addiction Models  
 Developing behavioral measures that more closely resemble those used to define 
addiction in humans may also be useful for establishing reliable predictors of opioid SA in 
preclinical models (Belin-Rauscent et al., 2016). Much as the Diagnostic and Statistical 
Manual of Mental Disorders (DSM) is utilized to measure addiction in humans (American 
Psychiatric Association, 2013), Belin and colleagues proposed a checklist approach to 
classifying addiction behavior in rats (Belin & Deroche-Gamonet, 2012). Three measures 
of drug SA were selected, each corresponding to a DSM diagnostic criterion, with the total 
score taken as the addiction score. In theory, other criteria, such as tolerance and 
withdrawal severity, could be similarly incorporated into such a model.  
 Alternatively, a number of researchers have modeled addiction in rodents by 





reinforcers such as social interaction, financial stability, etc. (Heyman, 2009; Townsend et 
al., 2019). This approach emphasizes the availability of non-drug rewards that compete 
with drugs for the individual’s attention and efforts to obtain. With the flexibility of SA, 
one can establish reliable procedures to assess individual differences in choice between 
drug and food or between drug and social interaction (Banks & Negus, 2017; Venniro & 
Shaham, 2020). In a recent study utilizing these procedures, Townsend and colleagues 
found that although female rats self-administered more fentanyl than males when it was 
the only reinforcer, males self-administered more fentanyl when the drug was available 
with an alternative food reinforcer (Townsend et al., 2019). By establishing choice 
procedures and examining the relationship between various predictors of individual 
differences in choice between drug and ethologically valid, non-drug reinforcers, 
researchers could add to the existing preclinical literature that views addiction primarily as 
a disorder of disinhibition (Belin et al., 2016; Townsend et al., 2019; Smith & Pitts, 2012).  
Multivariate Designs and Statistics 
Utilizing Multivariate Designs in Addiction Research  
 Studies in which more than one outcome is simultaneously observed and analyzed 
provide unique information about the clustering and interactions of different factors 
contributing to the behavioral outcomes of interest. Human studies have long incorporated 
multivariate designs and corresponding statistical methods to reveal complex relationships 
between large numbers of predictors and outcome measures of addiction (Krueger et al., 
2002; Ahn & Vassileva, 2016; Lynskey & Agrawal, 2007). For example, using elastic net 





identified distinct groups of personality traits associated exclusively with amphetamine or 
heroin use.  
 Multivariate study designs also allow us to examine the potential role of a reduced 
set of unobservable “latent” variables in accounting for variability among a much larger 
number of related variables. Such variables have greater statistical reliability than 
individual measures and have been valuable in characterizing core dimensions contributing 
to addiction vulnerability (Krueger et al., 2002; Lynskey & Agrawal, 2007; Monga et al., 
2007). In the human literature, some exploratory factor analysis (EFA) studies have 
suggested a single latent variable underlying many aspects of opioid addiction (Lynskey & 
Agrawal, 2007), while others have indicated 2 or 3 factors, each underlying different 
aspects of the disorder (Monga et al., 2007).  
In contrast to EFA, confirmatory factor analysis (CFA) provides a method for 
testing a priori theory-driven models of factor structure (Schmitt, 2011). This approach has 
shown that alcohol abuse risk reflects both a general liability to abuse of differing 
substances along with distinctive influences that give rise to alcohol abuse specifically (e.g., 
genetic variants in alcohol metabolizing enzymes) (Krueger et al., 2002; Tsuang et al., 
1998; Luczak et al., 2006). By adopting EFA and CFA methods, preclinical studies could 
complement human opioid addiction research in identifying dimensions underlying 
addiction vulnerability and their biological substrates.   
 Latent variable analyses would also help in improving the ability of animal models 
to capture important facets of human behavior and psychopathology. Most animal studies 





important insight on cause and effect. However, broader application of such insights may 
be limited by sources of variability specific to each individual trait measure or outcome 
measure. Such idiosyncrasies may be associated with a specific measure or paradigm (e.g. 
speed of learning in a conditioning paradigm), or the manner in which that paradigm is 
conducted in a specific lab. This variability can make it difficult to generalize across 
different preclinical studies, or from preclinical to clinical studies. Since latent variables 
capture only the commonality between a number of observed measures (e.g., demand and 
choice, measured in the same animals), they are relatively impervious to the idiosyncratic 
and unique variability of each observed measure. Therefore, latent variable analyses can 
provide more robust information about the relationships between observed measures and 
underlying constructs. 
Multivariate Designs in Preclinical Studies  
 A recent study used linear mixed-effects modeling to determine the predictability 
of demand for heroin as a function of one or multiple stress reactivity measures (Stafford 
et al., 2019). The results showed that models including multiple predictors explained a 
greater proportion of variance in heroin demand than did any bivariate model, 
demonstrating the value of incorporating multiple measures.  Linear model and factor 
analytic approaches have begun to be used to identify predictors of individual differences 
in psychostimulant SA (e.g., Dickson et al., 2015; Marusich et al., 2011; Belin et al., 2008; 
Deroch-Gamonet et al., 2014). Nevertheless, multivariate designs and statistical methods 
have been underutilized in preclinical studies of addictive drugs in general and of opioids 





existing or published datasets could also be re-analyzed with multivariate statistics when 
applicable, to further establish latent factors underlying addiction severity, as well as help 
identify clusters of behavioral traits that are most closely associated with these latent 
factors.  
Small Sample Size Multivariate Analyses  
 One of the biggest challenges to incorporating multivariate statistics methods in 
preclinical research is a common reliance on small sample sizes. Estimates for the 
minimum sample size required for a factor analysis have ranged widely e.g., N = 100-250 
(Cattell, 1978; Gorsuch, 1983; Guilford, 1954; Kline, 1979).  Most of these recommended 
sample sizes are impractical for preclinical behavioral studies. This may be a primary 
reason why between-group approaches have been favored over within-subject, factor-
analytic approaches in the preclinical literature. It is encouraging, therefore, to note the 
incorporation of much larger sample sizes (e.g., >1000 rats) in several recent or ongoing 
studies in outbred Heterogeneous Stock (HS) rats in order to conduct genomic analyses of 
complex traits (Gileta et al., 2018; Hughson et al., 2019).  
 While such studies are unlikely to become commonplace, it is now feasible with 
advances in quantitative psychology and statistics to conduct factor analysis and structure 
equation modeling with much smaller sample sizes. For example, the regularization 
method involves shrinking or adding penalties to specific parameters within the statistical 
models. The viability of this approach for conducting factor analysis and structure equation 
modeling using small sample sizes has been demonstrated in both simulation and human 





regularization provides reasonable factor recovery (i.e., how close the sample factor 
loadings are to population factor loadings) with sample sizes as small as N=5 and N=10 
(albeit, less than can be achieved with much larger sample sizes), and yields stable factor 
loadings when the number of measured variables is large (Jung & Lee, 2011). Greater use 
of these methods could enable preclinical studies with smaller sample sizes to implement 
complex models and test hypotheses more comparable and relevant to those tested in 
clinical addiction research.  
Conclusions 
 Despite the prevalence of opioid addiction and the societal burden it imposes, few 
factors have been associated with opioid addiction vulnerability in humans or animals. By 
utilizing more clinically relevant measures of drug addiction, and by further adopting and 
adapting data analytic tools commonly used in human studies, preclinical behavioral 
studies may further increase the construct and predictive validity of opioid SA and provide 
new insights into factors associated with vulnerability to opioid addiction, their genotypic 
and neurobiological basis, and their potential role in prevention and treatment.  
 The goal of this dissertation was to provide novel insights into individual 
differences in behavioral predictors of opioid addiction vulnerability. Studies 1 and 2 (see 
Chapters 2 & 3) examined two potential behavioral predictors of opioid addiction 
vulnerability, using a variety of morphine SA measures, while Study 3 (see Chapter 4) 
adapted novel statistical methods to explore the latent factor structure underlying morphine 





Chapter 2: Locomotor Activity Does Not Predict Individual Differences in 
Morphine Self-administration in Rats 
Opioid addiction poses a tremendous burden on public health (Center for 
Behavioral Health Statistics and Quality, 2013; Center for Behavioral Health Statistics and 
Quality, 2015).  Although many people experiment with opioids, only a minority undergo 
the loss of control over drug use that defines addiction (American Psychiatric Association, 
2013; Belin et al., 2016). Understanding the behavioral and neurobiological mechanisms 
contributing to individual differences in opioid addiction vulnerability is essential for 
developing more effective preventions and treatments.  
Sensation-seeking, or the pursuit of novel and intense experiences and a willingness 
to take risks in order to attain such experiences (Zuckerman, 1994), has been implicated in 
vulnerability to addiction to a variety of drugs including stimulants (e.g. cocaine, 
amphetamine) and alcohol (Bardo et al., 2013; Belin et al., 2016; Hittner & Swickert, 2006; 
Piazza et al., 1989). However, the relationship between sensation-seeking and opioid 
addiction vulnerability has not been well established. Some studies have shown a positive 
relationship between sensation-seeking and opioid use in humans (Franques et al., 2003; 
Kosten et al., 1994; Vest et al., 2016), while others have shown either no relationship 
(Conrod et al., 2000; Marino et al., 2013; Nielsen et al., 2012) or a negative relationship 
(Ahn & Vassileva, 2016).  The reasons for these discrepancies across studies are unclear, 
but may reflect differences in subject characteristics (e.g., age, sex, drug use history, and/or 
comorbidities), measure(s) of sensation-seeking, or other factors (Marino et al., 2013). 





could be useful for understanding the role of sensation-seeking in opioid addiction 
vulnerability. Spontaneous locomotor activity in a novel environment is a commonly used 
preclinical model of sensation-seeking (Blanchard et al., 2009; Pawlak et al., 2008; Piazza 
et al., 1989).  Consistent with the relationship between sensation seeking and stimulant use 
in humans, higher activity reliably predicts greater self-administration (SA) of stimulants 
(e.g., cocaine, amphetamine), particularly in terms of acquisition (Belin et al., 2008; Belin 
et al., 2011; Belin & Deroche-Gamonet, 2012; Piazza et al., 1989; Piazza et al., 2000).   
Only limited data are available regarding the relationship between spontaneous 
locomotor activity and individual vulnerability in i.v. opioid SA.  In a comparison between 
several inbred rat strains, those strains with higher activity levels also exhibited greater 
acquisition of morphine SA under certain conditions (Ambrosio et al., 1995; see Discussion 
for further details). However, the relationship between locomotor activity and opioid SA 
in outbred rodents has not been evaluated. This represents an important research gap given 
that inbred and outbred rats are genetically distinct, and because findings on predictors of 
addiction vulnerability in inbred and outbred rat strains are not always concordant (Cadoni 
et al., 2015; Chaouloff et al., 1995; Dilleen et al., 2012; Meyer et al., 2010).     
The primary goal of this study was to evaluate locomotor activity as a predictor of 
individual differences in the acquisition of morphine SA in outbred rats.  Because activity 
did not predict acquisition of morphine SA under the conditions initially studied (0.5 
mg/kg/infusion, 4 hr/day sessions), we evaluated the generality of this finding to a different 
model with a lower dose and shorter access period (0.2 mg/kg/infusion, 2 hr/day sessions).  





(e.g. cocaine) can be more apparent when lower unit doses and/or shorter access periods 
are used (Belin et al., 2016; Kabbaj, 2006; Mantsch et al., 2001).    
A secondary goal was to apply a behavioral economics framework to the analysis 
of individual differences in morphine SA.  Behavioral economics involves evaluation of 
the extent to which consumption of a reinforcer (e.g., drug) is maintained following 
increases in its unit price, which in drug SA models is operationalized as the cost-benefit 
ratio of response requirement/unit dose (Bickel et al., 2000; Hursh, 1991; Hursh & 
Silberberg, 2008).  Behavioral economics has been useful for studying individual 
differences in elasticity of demand (i.e., reinforcing efficacy) of numerous addictive drugs 
(e.g., cocaine) in both humans and animals (Diergaarde et al., 2008; Grebenstein et al., 
2013, Hursh & Silberberg, 2008, LeSage et al., 2016), but has not yet been applied to 
morphine SA in rodents.  Therefore, we evaluated elasticity of demand in animals that 
acquired morphine SA in both experiments in order to 1) evaluate the precision and 
generalizability of a behavioral economic framework in the context of morphine SA, and 
2) provide a preliminary evaluation of the relationship between locomotor activity and 
individual differences in behavioral economic measures. 
Materials and Methods 
Animals 
Male adult Sprague Dawley rats (Envigo, Indianapolis, IN) weighing 276-300 g at 
arrival were used.  All rats were individually housed in a temperature- and humidity-
controlled colony room with unlimited access to water under a reversed 12-h light/dark 





Beginning one week following arrival, food was restricted to 18 g/day to facilitate operant 
performance, avoid detrimental health effects of long-term ad libitum feeding, and limit 
catheter migration.  Protocols were approved by the Institutional Animal Care and Use 
Committee of the Minneapolis Medical Research Foundation in accordance with the 2011 
National Research Council’s Guide for the Care and Use of Laboratory Animals and the 
2003 National Research Council Guidelines for the Care and Use of Mammals in 
Neuroscience and Behavioral Research. 
Apparatus 
Locomotor Activity 
Locomotor activity was monitored in 43 x 43 cm open field activity chambers (Med 
Associates, Inc., St. Albans, VT). Each chamber had two 16-beam photocell arrays placed 
5 cm and one array 18 cm above the chamber floor to monitor horizontal and vertical 
activity, respectively. Chambers were placed inside sound-attenuating cubicles equipped 
with exhaust fans that provided masking noise and ambient lighting. Open-field activity 
software (Med Associates) was used for operating the apparatus and recording data. 
Morphine Self-Administration  
Self-administration (SA) sessions were conducted using 16 standard operant 
conditioning chambers (model ENV-007, Med Associates, Inc).  Each chamber contained 
two response levers, a white stimulus light located 2 cm above each lever, and a house light 
that provided ambient illumination.  Each chamber was placed inside a sound-attenuating 
cubicle equipped with an exhaust fan that provided masking noise.  An infusion pump 





a rate of 100 µl/kg per second. MED-PC IV software (Med Associates) was used for 
operating the apparatus and recording data. 
Drugs 
Morphine sulfate (NIH National Institute on Drug Abuse Drug Supply Program, 
Bethesda, MD) was dissolved in sterile saline and heparin (30 units/ml) was added to 
maintain catheter patency.  Morphine doses are expressed as the weight of the salt. 
Surgical Procedures 
Each rat was implanted with a chronic indwelling catheter into the right jugular 
vein under isoflurane (1%-3%) anesthesia, using general surgical procedures described in 
detail elsewhere (Harris et al, 2008; LeSage et al, 2002).  The catheter was externalized 
between the scapulae and attached to A vascular-access harness (VAH95AB, Instech 
Laboratories, Plymouth Meeting, PA) that allowed connection to a fluid swivel via a tether 
for morphine administration.  Animals were allowed to recover for one week after surgery, 
during which time they received daily i.v. infusions of heparinized saline, ceftriaxone 
antibiotic (5.25 mg, first three days only), and s.c. injections of buprenorphine (0.05 mg/kg; 
first two days only) for analgesia.  Infusions of methohexital (0.1 ml, 10 mg/ml, i.v.) were 
administered to check patency post-session on Fridays throughout all protocols. If a 
catheter became occluded (indicated by a failure of the animal to exhibit anesthesia within 
3-5 sec after methohexital infusion), another catheter was implanted into the ipsilateral 








Six days after arrival, rats (N = 16) were monitored for locomotor activity in a novel 
open field for 2 hours.  At least 24 hours later, rats were catheterized as described above. 
After a 7-10-day recovery period, rats were allowed to acquire i.v. morphine SA during 
daily 4 hr sessions conducted Mon-Fri.  During each session, responding on the left 
(“active”) response lever resulted in an i.v. infusion of morphine sulfate at a unit dose (0.5 
mg/kg/infusion) that maintains robust SA and that has previously been used to evaluate 
other determinants (e.g., pain sensitivity) of individual differences in morphine SA (Park 
et al., 2012; Nishida et al., 2016). Each infusion was accompanied by offset of the house 
light and the onset of a white cue light above the active response lever.  Following a 5-
second timeout period, the cue light above the active lever was extinguished to signal 
availability of the next infusion. Responses on the other lever in the operant chamber (the 
“inactive” lever) were recorded but had no programmed consequences.  On the first day of 
acquisition (always a Friday), food powder was placed on the active lever to facilitate 
contact with the lever.  Data from this session were not included in the data analysis.  
Beginning the following Monday, rats were tested under an FR 1 schedule for at least 10 
sessions and until acquisition criteria were met (≥ 5 infusions per session, ≤20% coefficient 
of variation, and ≥ 2:1 response ratio on the active to inactive lever) across 3 sessions, at 
which point the FR was increased to FR 2 for at least 5 sessions and then to FR 3. We used 
a FR 3 schedule prior to unit dose manipulation in order to be consistent with previous 
studies evaluating elasticity of demand for other drugs (e.g, nicotine) in our lab 





rates were stable under the FR 3 schedule (same stability criteria as above), unit price was 
manipulated by progressively reducing the morphine unit dose according to the following 
progression: 0.3, 0.1, 0.05, 0.025, 0 mg/kg. Each unit dose was tested for 5 sessions. Four 
rats exhibited self-mutilation and were tested under an accelerated schedule in order to 
expedite the protocol.  These animals were tested in 1-3 sessions per unit dose at either 1 
(n = 3) or 2 (n = 1) of the 6 unit doses. All of these animals completed the standard 5 
sessions per unit dose for the remaining unit doses.  Data for these 4 animals did not impact 
our overall conclusions and are included in the analyses below. 
Experiment 2 
Rats (N = 22) were tested for locomotor activity as described in Experiment 1, 
catheterized, and allowed to acquire i.v. morphine SA at a unit dose of 0.2 mg/kg/infusion 
(n = 16) or 0 mg/kg/infusion (saline) (n = 6) in 2 hour/day sessions under a FR 1 schedule 
for at least 10 sessions.   A longer timeout period following each infusion (30 sec rather 
than 5 sec) was used in an attempt to avoid the self-mutilation observed in Experiment 1.  
No mutilation was observed at any point in this experiment.  In animals exhibiting stable 
SA at FR 1 (same criteria as above), the FR was increased every 5 sessions according to 
the following progression: FR 2, 3, 6, 12, 24, etc., until infusion rates declined by at least 
90% compared to FR1.  Unit price was manipulated via increases in FR requirement rather 
than decreases in unit dose for two reasons.  First, based on data from Experiment 1, it was 
unclear whether a dose-reduction protocol using a 0.2 mg/kg/infusion training dose would 
provide a sufficient number and range of unit prices for a behavioral economic analysis 





demand function for describing morphine consumption when unit price was manipulated 
in this manner. In theory, increasing unit price via dose reduction or FR escalation should 
produce functionally equivalent effects on consumption (Bickel et al., 1995; Greenwald & 
Hursh, 2006). 
Statistical Analyses 
 All statistical analyses and graphing were performed either in GraphPad Prism 7 or 
R (ver. 3.2.3).  Locomotor activity was measured as total distance traveled (in cm) during 
the 2-hour activity test and was analyzed using one-way ANOVA. Secondary measures of 
activity included ambulatory count (horizontal photobeam breaks), stereotypic count 
(repetitive horizontal photobeam breaks) and vertical count (vertical photobeam breaks). 
In general, lever presses or infusions during morphine SA were analyzed using ANOVA 
followed by Sidak’s or Dunnet’s multiple comparison tests (see Results for more details). 
The primary measure of morphine SA acquisition was the mean number of infusions per 
session during the first 10 days of acquisition. Secondary measures of acquisition were 1) 
mean number of infusions during the first 10 minutes of each session during the first 10 
days of acquisition, a period that can be especially sensitive for detecting predictors of 
morphine SA (Nishida et al., 2016), and 2) number of days to achieve acquisition criteria. 
Pearson’s correlation was used to examine relationships between locomotor activity and 
measures of morphine SA acquisition and demand (see below). To confirm that collapsing 
locomotor data across the entire 2 hour locomotor session did not obscure a relationship 
between early-session activity and morphine SA, these correlational analyses were 





in an additional analysis, measures of morphine SA were compared between subgroups of 
rats designated as high or low responders based on whether their 2 hour activity level was 
above or below the median of the sample (see Dellu et al., 1996; Piazza et al., 1989; Piazza 
et al., 2000). In both experiments, these comparisons yielded the same conclusions as the 
correlational analyses and are not reported.  
To determine elasticity of demand (reinforcing efficacy) during unit dose reduction 
(Experiment 1) or FR escalation (Experiment 2), exponential demand curve analyses were 
conducted using the following equation: 
𝐿𝑜𝑔 𝑄 = 𝐿𝑜𝑔𝑄 + 𝑘(𝑒 − ∙ ∙ − 1) 
In this model, Q is the quantity consumed. The independent variable, C, is the cost of 
morphine based on the unit price (FR/unit dose). The free parameters, Q0 and α are 
estimated from the best-fit function and refer to the maximum level of consumption at zero 
price (i.e., level or “intensity” of demand) and the rate of change in consumption with 
increases in unit price, respectively. The range of the exponential function, k is a constant 
specifying the range of consumption in log units. The k value is held constant across all 
data sets being compared in each experiment (set to 2.3 in Experiment 1 and 1.8 in 
Experiment 2), because changes in k impact the value of α. The α parameter is considered 
a measure of reinforcing efficacy, such that drugs that produce rapidly declining (elastic) 
demand curves have higher α values and lower reinforcing efficacy than demand curves 
with slower declining (inelastic) demand curves. Therefore, α served as the index of 
elasticity of the demand for, or the reinforcing efficacy of morphine. Other demand 





Omax, the maximal response output; and Pmax, the unit price at which maximal response 
output occurred. Demand functions were generated using a template for GraphPad Prism 





 One-way ANOVA of locomotor activity in rats that later completed at least 10 days 
of morphine self-administration (SA) indicated a main effect of time (F(6.939, 104.1) = 
43.35, p < 0.0001).  Activity levels were highest during the first 30 minutes of the 2-hour 
session (Fig 1A), consistent with previous literature (e.g., Piazza et al., 1989).  
Acquisition 
All data were removed for one rat that pulled out its catheter following 8 acquisition 
sessions and died during i.v. catheter re-implantation. A two-factor ANOVA on data for 
the remaining 15 animals indicated a significant main effect of lever (F(1, 14) = 119.2, 
p<0.0001), but no main effect of session or interaction during the first 10 acquisition 
sessions (Fig 1B). Sidak's multiple comparisons test further showed significant differences 
in responding on the active versus inactive levers during all 10 sessions (t = 5.24 – 6.93, 
p<0.0001). Infusion rate did not differ significantly across sessions (Fig 1C).   









Table 3.   
 
Exponential demand curve parameters for individual subjects  
Subject α Q0 Pmax Omax R2 
Experiment 1      
1 0.00046 23.0 22.8 168.5 0.89 
2 0.00057 17.0 24.9 136.0 0.91 
3 0.00078 14.0 22.1 99.4 0.83 
4 0.00060 9.9 40.6 129.2 0.95 
5 0.00070 14.0 24.6 110.8 0.85 
6 0.00048 13.0 38.6 161.5 0.96 
7 0.00079 9.9 30.8 98.1 0.98 
8 0.00290 1.7 48.9 26.7 0.81 
9 0.00078 15.0 20.6 99.4 0.98 
10 0.00100 12.0 20.1 77.5 0.96 
11 0.00320 2.6 29.0 24.2 0.89 
12 0.00092 13.0 20.2 84.3 0.96 
13 0.00100 17.0 14.2 77.5 0.92 
14 0.00130 19.0 9.8 59.6 0.97 
Mean 0.00111 12.94 26.23 96.62 0.92 
SEM 0.00229 1.54 2.83 11.62 0.02 
      
Experiment 2      
1 0.00160 6.8 29.7 64.3 0.65 
2 0.00650 12.0 4.1 15.8 0.83 
3 0.00150 4.7 45.8 68.6 0.85 
4 0.00098 6.2 53.1 105.0 0.92 
5 0.00240 4.8 28.0 42.9 0.77 
6 0.00140 8.4 27.4 73.5 0.92 
7 0.00058 11.0 50.6 177.4 0.91 
8 0.00076 3.5 121.3 135.4 0.85 
Mean 0.00197 7.18 45 85.36 0.84 
SEM 0.00068 1.08 12.27 18.36 0.03 
      






 One rat did not complete dose-response testing due to multiple catheter 
occlusions.   Data for this animal have been removed.  One-way ANOVA on data for the 
remaining animals revealed a significant effect of dose on number of infusions (F (1.786, 
23.21) = 19.91, p<0.0001). Post-hoc Dunnett's multiple comparisons test showed that 
infusions at 0.05, 0.1, 0.3, 0.5 mg/kg/infusion were all significantly higher than at 0 
mg/kg/infusion (q = 4.41 – 6.35, p < 0.0001-0.003), while there was only a marginally 
significant difference between infusions at 0.025 versus 0 mg/kg/infusion (q = 2.69, p= 
0.0686, see Fig 1D). 
Morphine consumption during demand testing was well-described by an 
exponential demand function, with R2 values typically ≥ 0.85 for individual animals and 
R2 = 0.97 for rats as a group (Table 3, Figure 1E). There was a considerable degree of 
individual variability in α values (i.e., elasticity of demand), with some rats showing a rapid 
decline in morphine consumption following increases in unit price (i.e., reductions in unit 
dose) (e.g., rat #14 in Table 3 and Fig 1E) and others maintaining significant consumption 
despite the increases in unit price (e.g., rat #6 in Table 3 and Fig 1E).   
Correlations  
Pearson’s correlation indicated that total distance traveled during the 2-hour 
locomotor test was not correlated with average daily infusion rate during acquisition of 
morphine self-administration (SA) (r = 0.05, p = 0.86), average infusions during the first 
10 minutes of each session during acquisition (r = -0.21, p = 0.46) (Figure 2A-B), or days 
to acquire (r = 0.23, p = 0.41) (Figure 2C; n = 15). Moreover, distance traveled during 





0.70) (Figure 2D), intensity of demand (maximum consumption at zero price) (r = 0.10, p 
= 0.73) (Figure 2E), Pmax (r = 0.14, p = 0.63), or Omax (r = 0.18, p = 0.55) (data not shown 
graphically; n = 14). Consistent with the above analyses, activity during the first 30 minutes 
of the 2 hour locomotor test was not correlated with average daily infusion rate during 
acquisition (r = 0.31, p = 0.26) or any other measure of morphine SA (data not shown).  
Secondary activity measures including ambulatory count (mean ± SEM = 2027.7, SEM = 
181.1), stereotypic count (12403.3,± 702.1) and vertical count (208.7  ± 21.5) were not 
significantly correlated with average daily infusion during acquisition or other measures of 
morphine SA (all p  0.33) (data not shown). 
Experiment 2 
Locomotor Activity 
As in Experiment 1, one-way ANOVA of locomotor activity indicated a main effect 
of time (F(7.058, 105.9) = 69.27, p < 0.0001), with most activity occurring during the first 
30 minutes of the 2-hour session (Fig 3A). 
Acquisition 
A three-factor ANOVA (lever x drug x session) indicated significant main effects 
of lever (active vs inactive) (F(1, 20) = 10.70, p=0.004) and drug (morphine vs. saline) 
(F(1, 20) = 10.25, p=0.004), and a significant lever x drug interaction (F(1, 20) = 5.14, 
p=0.035). There was no main effect of session or other interactions. A two-factor ANOVA 
on data for the morphine group indicated a significant effect of lever (F (1, 15) = 22.16, 
p=0.0003), but no effect of session or interaction (Fig 3B). Sidak's multiple comparisons 





levers during all 10 sessions (t = 3.33 – 6.46, p<0.01). Analysis of active and inactive lever 
data for rats in the saline group indicated no effect of lever, session, or interaction. 
 Analysis of infusion rates indicated a significant effect of drug (F (1, 20) = 11.36, 
p=0.0030), but no effect or session or interaction (Fig 3C). 
Elasticity of Demand 
None of the animals in the saline group were tested for demand because none of 
them achieved SA acquisition criteria.  Eight of the 16 animals in the morphine group did 
not complete this phase due to failure to acquire, loss of catheter patency, or other problem. 
One-way repeated measures ANOVA on data from the 8 remaining animals revealed 
significant effect of FR on number of morphine infusions (F (1.941, 15.53) = 21.29, 
p<0.0001). Post-hoc Dunnett's multiple comparisons test showed that infusions at FR 12, 
24 and 48 were all significantly lower than at FR 1 (q = 3.94 – 6.62, p = 0.02-0.0007). 
Infusions at FR 6 only marginally differed from infusions at FR 1 (q = 3.00, p= 0.07) (Fig 
3D). 
Morphine consumption during demand testing was generally well-described by an 
exponential demand function (R2 = 0.96 for rats as a group, Fig 3E), with considerable 
individual variability in α values (Table 3).  
Correlations 
Distance traveled during the 2-hour locomotor test was not correlated with average 
daily infusion rate during acquisition of morphine SA (r = 0.06, p = 0.82, n = 16), average 
infusions during the first 10 minutes of each session (r = -0.16, p = 0.56, n = 16) (Figure 





traveled did not predict elasticity of demand (r = -0.21, p = 0.62) (Figure 4D), intensity of 
demand (r = -0.13, p = 0.77) (Figure 4E), Pmax (r = 0.30, p = 0.47), or Omax (r = 0.20, p 
= 0.64) (data not shown graphically; n = 8 for all behavioral economic measures). Activity 
during the first 30 minutes of the 2 hour locomotor session also was not correlated with 
average daily infusion rate during acquisition (r =  0.002, p =  0.99) or any other measures 
of morphine SA (data not shown). Other measures including ambulatory count (mean ± 
SEM = 2640.9, 177.5), stereotypic count (14046.4 ± 755.6) and vertical count (228.3 ± 
15.7) were not correlated with average daily infusion during acquisition or other measures 





























Figure 1. (A) Mean (± SEM) distance traveled in 5-minute blocks during locomotor testing. 
Mean (± SEM) number of response on the active and inactive levers (B) and infusions per 
session (C) during acquisition in Experiment 1. (D) Mean (± SEM) number of infusions at 
each morphine SA unit dose during demand testing.  (E) Exponential demand curve 
describing morphine consumption as a function of unit price for rats as a group.  Demand 
curves for individual rats with relatively low (rat #6) and high (rat #14) elasticity of demand 

































































































































Figure 2. Relationship between distance traveled during the 2 hour locomotor activity test 
and (A) mean daily infusions during the first 10 sessions of acquisition, (B) mean daily 
infusions during the first 10 minutes of each session during the first 10 acquisition sessions, 
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Figure 3. (A) Mean (± SEM) distance traveled in 5-minute blocks during locomotor testing. 
Mean (± SEM) response on the active and inactive levers (B) and total infusions per 
session (C) during the first 10 sessions of acquisition in rats responding for morphine (0.2 
mg/kg/inf) or saline (0 mg/kg/inf) rats in Experiment 2. (D) Mean (± SEM) number of 
infusions at FR during demand testing. (E) Exponential demand curve describing morphine 



































0.2 mg/kg/inf 0 mg/kg/inf 
**














































































Figure 4. Relationship between distance traveled during the 2 hour locomotor activity test 
and (A) mean daily infusions during the first 10 sessions of acquisition, (B) mean daily 
infusions during the first 10 minutes of each session during the first 10 acquisition sessions, 
(C) number of days to acquire; (D) elasticity of demand (log ), and (E) intensity of 
demand (Q0) in the morphine SA group.  There are fewer data points for (C-E) than in (A) 
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The main finding of this study is that spontaneous locomotor activity did not 
predict acquisition of morphine self-administration (SA) in rats using two distinct 
morphine SA protocols.  
To the extent that activity in an open field is relevant to sensation-seeking, our data 
are consistent with some human studies indicating a lack of positive relationship between 
sensation seeking and opioid addiction vulnerability (Ahn & Vassileva, 2016; Marino et 
al., 2013; Nielsen et al., 2012). For example, a recent analysis showed that high sensation-
seeking and impulsivity are predictors of greater vulnerability to amphetamine addiction 
but not heroin addiction (Ahn & Vassileva, 2016). In contrast, other human studies indicate 
that sensation-seeking is positively associated with opioid addiction vulnerability (Cheng 
et al., 2015; Franques et al., 2003; Kosten et al., 1994). Taken together, these data suggest 
that the relationship between sensation-seeking and opioid addiction vulnerability may be 
complex and may not be observable under all conditions. 
Our data with outbred rats contrast with a previous report that inbred rat strains 
with higher rates of spontaneous locomotor activity also exhibited greater acquisition of 
morphine SA (Ambrosio et al., 1995). This discrepancy may reflect genetic differences 
between outbred and inbred rat strains (Zhou et al., 2008) and/or our use of a within-strain 
rather than between-strain comparison. In addition, the significant between-strain 
correlation reported in Ambrosio et al. (1995) was only observed when activity was 
measured after catheterization. This relationship was lost when activity was measured 





of locomotor activity), which is the approach used in this study and most others evaluating 
activity/drug SA relationships. These factors, as well as other methodological differences 
across studies (e.g., unit dose), could account for the difference.  
Based on their findings that spontaneous locomotor activity predicted acquisition 
of both food and cocaine SA, Mitchell and colleagues suggested that locomotor activity 
predicts a general learning capability for operant lever pressing rather than drug use 
propensity per se (Mitchell et al., 2005).  Our findings that locomotor activity did not 
predict acquisition of morphine SA contrasts with this prediction, and suggests that the 
relationship between activity and self-administration may be more complex.  
Our current extension of behavioral economics to morphine SA further supports the 
precision, generalizability, and utility of this analytical approach. An exponential demand 
function described morphine consumption well, consistent with findings using drugs and 
other reinforcers in animals and humans (Grebenstein et al., 2013, Hursh, 1991, Hursh & 
Silberberg, 2008). Importantly, considerable individual differences were observed in α in 
both studies (Table 3), supporting the use of this approach to measure individual 
differences in addiction vulnerability.  Evaluation of other factors (e.g., opioid withdrawal 
sensitivity) as determinants of individual differences in demand for morphine is warranted. 
The primary goal of this study was to understand the relationship between 
locomotor activity and morphine SA rather than direct comparison between the 
determinants of individual differences in morphine versus stimulant addiction. 
Nonetheless, our data contrast with findings indicating that activity reliably predicts 





nicotine) (Belin et al., 2011, Belin et al., 2016, Suto et al., 2001; Turner et al., 2008; Piazza 
et al., 2000).  They also complement studies that other predictors of stimulant SA (e.g., 
impulsivity) do not predict individual differences in opioid SA (Ahn & Vassileva, 2016; 
Dilleen et al., 2012; McNamara et al., 2010).  The cause of these potential differences 
across drug classes is unclear, but may include differences in their neurobiological effects 
(e.g. drug-induced synaptic and structural plasticity) or different needs for self-medication 
(Badiani et al., 2011; Markou et al., 1998).  That is, due to the different psychoactive effects 
of opioids versus stimulants (e.g., anxiolytic effects versus arousal), individuals with 
varying psychological characteristics (e.g., degree of sensation-seeking) might prefer one 
drug class over the other (Khantzian, 1985; Markou et al., 1998).  
Alternatively, the lack of concordance between the current findings and those with 
other drugs may reflect methodological factors unique to this study (rat strain, equipment, 
etc.) rather than our use of an opioid instead of other drugs. However, the rat strain, 
equipment, and general procedure used here were almost identical to that used in several 
studies reporting positive relationships between activity and acquisition of SA of non-
opioids (e.g., Belin et al., 2008; Smith et al., 2015; Suto et al., 2001).  Furthermore, the 
ability of activity to predict acquisition of SA of other drugs has remained robust despite 
numerous methodological differences across studies and laboratories including variations 
in rat strain, method of activity assessment (e.g., circular runway versus open field), 
operant response (lever press versus nose-poke), etc. Indeed, locomotor activity has been 
described as the most reliable predictor of acquisition of drug SA in the preclinical 





inclusion of a positive control group tested under the same conditions but responding for a 
stimulant (e.g., cocaine) in future studies is needed to confirm that our findings reflect a 
true difference in predictors of SA across drugs. Further evaluating the relationship 
between activity and opioid SA using other unit doses, durations of access, types of opioids, 
etc., is also needed to confirm the generality of our findings. Understanding the ability of 
other putative measures of sensation-seeking (e.g., preference for a novel environment) 
(Belin et al., 2011; Cain et al., 2005) to predict individual differences in opioid SA is also 
of interest. 
There are several limitations to our study. First, group sizes were relatively small, 
which may have limited our ability to detect a significant relationship between activity and 
morphine SA.  However, previous studies have detected correlations between locomotor 
activity and acquisition of stimulant SA using similar or even smaller group sizes (e.g., 
Mitchell, Cunningham & Mark, 2005; Smith et al., 2015). Given the absence of even a 
trend for activity to predict acquisition measures in either experiment (see Fig 2 and 4), it 
is unlikely that the use of larger group sizes would have changed our conclusions regarding 
these relationships.  An additional limitation is that some rats in Experiment 1 exhibited 
self-mutilation during dose-response testing, which required testing some rats for a shorter 
number of days at 1-2 of the 6 unit doses. However, removal of data for these animals did 
not change our conclusions. Importantly, this issue was not present during acquisition, 
which was our primary outcome. 
While not a primary goal of this study, our use of open-field activity testing 





center of the activity chamber (i.e., thigmotaxis), a measure of anxiety-like behavior 
(Cohen et al., 2009; Prut & Belzung, 2003; Treit & Fundytus, 1988), and individual 
differences in morphine SA.  Anxiety has been linked to opioid addiction vulnerability in 
humans (Lejuez et al., 2008; Martins et al., 2012; Norton, 2001), and anxiety-like behavior 
in the elevated plus maze predicted individual differences in cocaine self-administration in 
rodents (Dilleen et al., 2012; Pelloux et al., 2009; Walker et al., 2009). We found that 
thigmotaxis did not predict individual differences in any measure of morphine SA, which 
is consistent with findings indicating that anxiety-like behavior in the elevated plus maze 
did not predict individual differences in heroin self-administration (Dilleen et al., 2012). 
In conclusion, our findings indicate that locomotor activity in a novel environment 
did not predict individual differences in morphine SA in rats.  These data complement 
findings from some human studies and suggest that the role of sensation-seeking in 






Chapter 3: Higher anhedonia during withdrawal from initial opioid exposure 
is protective against subsequent opioid self-administration in rats 
Opioid addiction poses a substantial burden on public health (Center for Behavioral 
Health Statistics and Quality, 2018; Jones et al., 2018). Identifying behavioral and 
neurobiological factors contributing to the marked individual differences in opioid 
addiction vulnerability is essential for developing more effective preventions and 
treatments (Belin et al., 2016; Wang et al., 2019).  However, few behavioral measures have 
been identified in preclinical models that reliably predict individual differences in i.v. 
opioid self-administration (SA).  SA is often considered the “gold standard” for modeling 
addiction-like behavior in animals because it involves volitional drug consumption as 
occurs in humans (Yap & Miczek, 2008).  
Sensitivity to the initial acute effects of drugs (e.g., euphoria, aversion) is a key 
predictor of addiction vulnerability in humans (O’Loughlin et al., 2003; DiFranza et al., 
2007; Schuckit et al., 2004) and the direction of the relationship depends on the drug effects 
measured. For example, greater aversive effects of initial drug exposure can be protective 
against the subsequent development of addiction (DiFranza et al., 2004; Fowler & Kenny, 
2014; Sartor et al., 2010).  Similarly, several preclinical studies indicate that sensitivity to 
the initial effects of acute drug injections (e.g., locomotor activity or depression, 
antinociception) predict voluntary drug intake in an i.v. SA model (Deminiere et al., 1989; 
Chappell & Weiner, 2008; Nishida et al., 2016).  
Acute drug injections also produce negative affective (emotional) states (e.g., 





are induced even after a single drug exposure in both humans and animals (“acute 
dependence”; Harris & Gewirtz, 2004; Liu & Schulteis, 2004; Schulteis et al., 2004; Harris 
& Gewirtz, 2005), and often become more severe with repeated drug exposures 
(Engelmann et al., 2004; Harris et al., 2004; Kenny et al., 2003). Some authors have 
proposed that greater sensitivity to the negative affective consequences of withdrawal may 
be protective against addiction (Carroll et al., 2008; Dess et al., 2005; Holtz et al., 2015; 
O’Dell, 2009; O’Dell et al., 2006), and that anhedonia may reduce the motivation for 
reward-seeking (Wise, 2004). Consistent with these predictions, rats selectively bred for 
high voluntary alcohol consumption showed lower withdrawal-induced anhedonia (WIA) 
after initial alcohol exposure (Chester et al., 2006). Similarly, it was found that saccharin-
preferring rats, which exhibit greater SA of opioids and other drugs (Carroll et al., 2002), 
exhibit lower WIA during withdrawal from acute morphine exposure (Holtz et al., 2015). 
Nevertheless, the relationship between sensitivity to withdrawal from acute drug exposure 
and drug SA has not been directly tested within the same animals or in outbred rats, which 
can differ from selectively bred rats in terms of determinants of addiction vulnerability 
(Ambrosio et al., 1995; Zhou et al., 2008). 
The goal of this study was to evaluate the ability of WIA to predict individual 
differences in subsequent i.v. morphine SA (MSA) in outbred rats. WIA was measured as 
increases in intracranial self-stimulation (ICSS) thresholds, which is one of the most 
commonly used measures of the anhedonic consequences of withdrawal from opioids and 
other drugs in rats and has considerable predictive validity (Bruijnzeel et al., 2007; Cahill 





demonstrating reduced WIA in rodents selectively bred for greater addiction vulnerability 
(Chester et al., 2006; Holtz et al., 2015) Several common measures of MSA (e.g., 
acquisition, demand, reinstatement) were used because they model distinct aspects of 
addiction and can be differentially associated with other behavioral predictors of drug SA 
(Belin et al., 2011; Belin et al., 2008). It was hypothesized that greater WIA severity would 
be associated with lower MSA vulnerability.  
Materials and Methods 
Overview of experimental protocol 
Male adult Sprague-Dawley rats were tested under the experimental protocol 
shown in Figure 5. Rats were first tested for WIA during naloxone-precipitated and 
spontaneous withdrawal from acute morphine injections (Phase 1).  Rats were then tested 
for opioid addiction vulnerability using several measures of i.v. MSA including 
acquisition, elasticity of demand, and reinstatement (Phase 2).  Finally, WIA was again 
tested to provide a preliminary characterization of the relationship between MSA and 
withdrawal sensitivity during a more advanced stage of dependence ("late-stage 
dependence", Phase 3).  
Acute dependence 
Rats were prepared and trained on a discrete-trial ICSS procedure (see 
Supplemental Material) in daily sessions conducted Mon-Fri until ICSS thresholds were 
stable (<10% variability over 5 days) and habituated to saline injections as described 
previously (see Harris et al., 2013). On the first test day, rats were injected with morphine 





rats were injected with the opioid antagonist naloxone (NX, 0 or 1.0 mg/kg, s.c.)  and tested 
for ICSS 10 minutes later. These morphine and naloxone doses and this pretreatment 
interval produce significant negative affective morphine withdrawal signs, including WIA 
(Schulteis et al., 2004; Harris et al., 2004; Holtz et al., 2015). Immediately after ICSS 
testing, somatic withdrawal signs were assessed as a secondary withdrawal measure (see 
Supplementary Material). There was a total of 4 groups in a 2 (MOR dose) x 2 (NX dose) 
factorial design.  The MOR + NX group (n = 29) was larger than the MOR + SAL, SAL + 
NX, and SAL + SAL groups (n = 10-11/group) in order to have adequate power for 
correlation analysis (see below). These procedures were repeated each day for 5 
consecutive days.  Animals were then tested for ICSS under drug-free conditions for at 
least one week and until ICSS thresholds were stable (same stability criteria as above).   
To test spontaneous withdrawal, the same rats received a single injection of 5.6 
mg/kg MOR (MOR+NX and MOR+SAL groups) or 0 mg/kg MOR (SAL+NX and 
SAL+SAL groups) and ICSS was tested 2, 6, 26, 30, 50, 64, 74, 98, and 170 hours later. 
The purpose of the 2 hour time point was to detect any reinforcement-facilitating (ICSS 
threshold-lowering) effects of morphine itself (see Altarifi & Negus, 2011). The selection 
of subsequent time points was based on the time course of spontaneous withdrawal from 
acute morphine exposure determined using ICSS and other measures (Harris & Gewirtz, 
2004; Rothwell et al., 2010; Liu & Schulteis, 2004). Somatic withdrawal signs were 
recorded immediately after ICSS testing at the 26 hour time point (based on Allahverdiyev 






Figure 5. Overview of experimental protocol. During the acute dependence phase (Phase 1), precipitated withdrawal was tested 
repeatedly over 5 consecutive days.   On each day, rats were injected with morphine (0 or 5.6, mg., s.c.), followed 1 hr 50 min later by 
naloxone (0 or 1.0 mg/kg), and then tested for ICSS 10 min later (length of ICSS session  45 min).  After precipitated withdrawal, rats 
were injected with morphine (0 or 5.6 mg/kg) and tested for ICSS 2, 6, 26, 30, 50, 64, 74, 98, and 170 hours later (Phase 2). After 
completion of spontaneous withdrawal testing, all animals were tested using various measures of MSA (e.g., acquisition, demand, 
reinstatement) in daily 2 hr sessions. Following completion of the MSA protocol, rats were again tested for precipitated and spontaneous 








Within 48 hours after the final ICSS test, locomotor activity in a novel environment 
(i.e., “sensation-seeking” (Blanchard et al., 2009; Pawlak et al., 2008; Piazza et al., 1989)) 
was tested for 2 hours as a secondary predictor of MSA. 
MSA 
Approximately 24-48 hours after completion of the locomotor activity test, animals 
from all groups were implanted with i.v. catheters using our standard procedures (see Study 
1).  Following a 7-10 day recovery period, all rats were allowed to acquire i.v. morphine 
SA (0.2 mg/kg/inf) during daily 2 hr sessions conducted Mon-Fri using our standard 
apparatus and procedures (see Supplementary Material). Rats were tested under a fixed 
ratio (FR) 1 schedule for at least 10 sessions and until acquisition criteria were met (≥5 
infusions per session, ≤ 20% coefficient of variation, and ≥  2:1 response ratio on the active 
lever to inactive lever) across 3 sessions. To test elasticity of demand (reinforcing efficacy), 
the FR requirement was increased every 3-4 sessions as follows: FR 2, 3, 6, 12, 24, and 
doubled thereafter until infusion rates during the last 2 sessions at a given FR were reduced 
by 90% compared to baseline (FR 1). Morphine consumption under this protocol is well 
described by the current exponential demand function (Hursh & Silberberg, 2008). Data 
from Mondays were excluded from data analysis to avoid potential spontaneous recovery 
of responding after the weekend. Therefore, if one of the three sessions at a given FR 
occurred on a Monday, rats were tested in an additional session at that FR.  
After completion of demand testing, rats were allowed to reacquire MSA under an 





above).  Extinction conditions were subsequently introduced in which the morphine dose 
was replaced with saline and the drug-associated cue light was no longer presented upon 
infusion. Extinction was tested for at least 10 sessions and until animals exhibited a 75% 
reduction in active lever pressing for 2 consecutive sessions.   
To test morphine- and cue-induced reinstatement, rats were injected s.c. on separate 
days with either saline or morphine (1.0 mg/kg) 10 min prior to the SA session. This 
morphine dose and pretreatment interval reliably reinstated drug-seeking in our lab (data 
not shown) and others (Vassoler et al., 2017). Responses on the active lever resulted in a 
saline infusion and either presentation of the drug-associated cue light (“cue” condition) or 
no programmed consequences (“no cue” condition). Reinstatement testing was therefore 
conducted using a 2 (morphine dose) x 2 (cue condition) design, resulting in a total of 4 
reinstatement tests.  These tests were conducted on Tuesdays and Fridays, provided that 
active lever pressing returned to extinction levels during the preceding session, and the 
order of reinstatement conditions was counterbalanced. Following completion of 
morphine- and cue-induced reinstatement testing, rats were tested under extinction 
conditions for at least 5 sessions and until extinction criteria were again met. Similar 
within-subject designs are commonly used to study reinstatement (Le et al., 1998; Liu & 
Weiss, 2002).  To test stress- and cue-induced reinstatement, the above procedure was 
repeated except that rats were injected i.p. with either deionized water or the stress-
inducing α2-adrenergic antagonist yohimbine (2.5 mg/kg) 30 min prior to each SA test. 
This dose of yohimbine and pretreatment interval reliably reinstate extinguished SA 





Late-stage dependence  
Following completion of all MSA procedures, rats were again tested for ICSS until 
thresholds were stable. Rats (N = 26) were subsequently tested for precipitated (MOR + 
NX: n = 14,  n =  4/group for other groups) and spontaneous (MOR: n = 15, SAL: n = 5) 
morphine withdrawal using the same protocol as described for acute dependence testing 
above. The small group sizes for this exploratory phase reflect the considerable attrition 
rate by this stage of the protocol (see Supplemental Materials).   
Statistical analysis 
ICSS 
 ICSS thresholds (a measure of brain reinforcement function) and response latencies 
(a measure of non-specific motoric effects; Markou & Koob, 1992) during naloxone-
precipitated and spontaneous withdrawal were measured as percentage of baseline (average 
of the last 5 days prior to onset of withdrawal testing). To provide a composite measure of 
naloxone-precipitated withdrawal severity for each animal, percentage scores were 
standardized into z-scores and then averaged across average and peak ICSS thresholds 
during all 5 precipitated withdrawal tests and degree of sensitization of WIA (the difference 
score in ICSS thresholds between test days 1 and 5) with the following formula:  
𝑍(average thresholds) + 𝑍(peak thresholds) + 𝑍(difference score of thresholds)
3
 
Spontaneous withdrawal severity was measured as peak withdrawal severity during hours 
6 – 98 after morphine injection.  This measure accounts for the considerable individual 
differences in the time course of changes in ICSS thresholds during spontaneous 





during 1 or 3 sessions and n = 1 for spontaneous withdrawal during 1 session) where rats 
failed to respond for any ICSS current intensity, we arbitrarily assigned ICSS threshold 
and latency values based on those obtained in the animal achieving the highest ICSS 
threshold in that phase of the experiment (see Harris et al., 2015; Markou & Koob, 1991). 
MSA 
MSA acquisition was measured as the mean number of infusions per session during 
the first 10 days of acquisition. To determine opioid reinforcing efficacy during FR 
escalation, exponential demand curve analyses were conducted as described in detail 
elsewhere Hursh & Silberberg, 2008). Consistent with previous studies (Diergaarde et al., 
2008; Hursh & Silberberg, 2008; Study 1), we used α as our primary demand measure.  
This outcome refers to the rate of change in consumption with increases in unit price 
(elasticity of demand), with higher α values indicating lower reinforcement efficacy. Zero 
values in consumption were replaced with 0.01 (1/10th of our lowest non-zero consumption 
level) to provide better curve fits and more accurate parameter estimates of demand for 
individual rats (Koffamus et al., 2015; Murphy et al., 2009). α values were log-transformed 
due to non-normal distribution. Extinction was measured as mean number of infusions per 
session during the first 10 sessions of extinction.  Degree of reinstatement (the 
reinstatement score) was defined as the difference between active and inactive lever 
responses during each reinstatement test (Cippitelli et al., 2010; Le et al., 2005; Tran-
Nguyen et al., 1998).  
 All statistical analyses and graphing were performed in GraphPad Prism 7 or R 





using ANOVA followed by Holm-Sidak’s or Dunnet’s multiple comparison tests (see 
Results for more details). Relationships between ICSS and MSA measures in the MOR + 
NX group were assessed using Pearson’s correlation.   
Results 
Acute dependence 
Precipitated withdrawal: ICSS  
 Baseline ICSS thresholds did not differ between groups (Table S1). A two-way 
ANOVA on ICSS thresholds during precipitated withdrawal revealed a significant main 
effect of group (F (3, 54) = 36.62, p < 0.0001) and a significant interaction between group 
and session (F (12, 216) = 3.181, p = 0.0003). Dunnett’s multiple comparisons indicated 
that ICSS thresholds were significantly elevated in the MOR+NX group compared to 
SAL+SAL controls during all 5 sessions (all q ≥ 3.162, all p ≤ 0.005). In contrast, 
thresholds in the MOR+SAL and SAL+NX groups did not differ from the SAL + SAL 
group during any session (Figure 6A). A repeated-measures ANOVA showed a significant 
effect of session in the MOR+NX rats (F (2.863, 77.30) = 18.40, p < 0.001), with Dunnett’s 
multiple comparisons indicating significantly higher ICSS thresholds during sessions 2-5 
compared to session 1 (all q ≥ 4.68, all p ≤ 0.001). In contrast, there was no effect of session 
in any of the control groups (all p > 0.05).  
No significant differences were observed in baseline ICSS response latencies 
between groups (Table S1). Latencies also did not differ between groups during 






Spontaneous withdrawal: ICSS 
Baseline ICSS thresholds did not differ between groups (Table S1).  ICSS threshold 
data during hours 2 (i.e., acute effect of MOR itself) and hours 6 – 98 (i.e., withdrawal 
period) of spontaneous withdrawal did not differ between the two groups receiving MOR 
(MOR + NX and MOR + SAL groups) or between the two groups receiving SAL (SAL + 
SAL and SAL + NX groups).  Therefore, data from these groups were combined into single 
MOR (n = 37) and SAL (n = 20) groups for further analysis. Welch’s corrected t-test 
showed no significant difference in ICSS thresholds between MOR and SAL rats 2 hours 
after injection (MOR: 107.7 ±5.35%; SAL: 100.4 ± 2.50%), indicating that MOR itself did 
not affect ICSS. Two-way ANOVA on ICSS thresholds during spontaneous withdrawal 6-
98 hours after morphine injection revealed a significant main effect of time (F (7, 385) = 
4.831, p < 0.0001) and group (morphine vs. saline) (F (1, 55) = 4.012, p = 0.05), but no 
significant interaction (Figure 6C). After correcting for multiple comparisons, ICSS did 
not significantly differ between groups at any individual time-point post injection.  
However, peak ICSS threshold values between hours 6 and 98 (regardless of the time point 
at which they occurred) differed significantly between the morphine (117.1 ± 2.15%) and 
saline (110.4 ± 1.63%) groups (Welch-corrected t(54.9) = 2.50, p = 0.02).  
 No significant differences were observed in ICSS response latencies between 
groups during baseline sessions (Table S1), 2 hours after injection (MOR: 103.2 ± 3.01%; 
SAL: 96.43 ± 1.82%), or during spontaneous withdrawal (Figure 6D).  





 One-way ANOVA on total somatic signs during the 5th session of naloxone-
precipitated withdrawal indicated a significant effect of group (F (3, 52) = 11.51, p < 
0.0001). Dunnett’s multiple comparison test revealed significantly higher scores in the 
MOR + NX group compared to the SAL + SAL group (q(52) =2.62, adjusted p = 0.03).  In 
contrast, neither the MOR + SAL or SAL + NX group differed significantly from the SAL 
+ SAL group (Figure 7A). 
Spontaneous withdrawal: Somatic signs 
During spontaneous withdrawal, somatic sign scores did not differ between the two 
groups receiving MOR (MOR + NX and MOR + SAL groups) or between the two groups 
receiving SAL (SAL + SAL and SAL + NX groups).  Data from these groups were 
therefore combined into a single MOR (n = 37) or SAL (n = 20) condition. T-tests showed 
that scores were significantly higher in the MOR condition compared to the SAL condition 
(Welch-corrected t(51.31) = 2.25, p = 0.03) (Figure 7B).  Eye blinking, facial fasciculations 
and swallowing movements were the most commonly observed somatic signs during both 
precipitated and spontaneous withdrawal (Table S4, S5).  
MSA in the Mor + NX Group 
Acquisition (n = 29) 
Two-way ANOVA revealed a significant main effect of lever (active vs inactive) 
(F (1, 28) = 58.38, p < 0.0001) and session (F (9, 252) = 2.896, p = 0.003) on responses 
during the first 10 days of acquisition (Figure 8A). Sidak’s multiple comparison test 
showed significantly higher responses on the active lever during all acquisition sessions 





Demand (n = 25 due to attrition, see Supplementary Material) 
Increases in FR requirement resulted in a progressive reduction in morphine 
consumption (Figure 8B). A one-way repeated measures ANOVA revealed a significant 
effect of FR on number of morphine infusions (F (3.59, 82.63) = 79.43, p < 0.0001). A 
post-hoc Dunnett's multiple comparisons test showed that infusions at all subsequent FRs 
were significantly lower than at FR 1 (all q ≥ 4.23, all p ≤ 0.002). Morphine consumption 
during demand testing was well-described by an exponential demand function, with R2 
values typically ≥ 0.80 for individual animals (Table S2) and R2 = 0.94 for rats as a group, 
with considerable individual variability in elasticity of demand (see Figure 8C).  
Extinction (n = 24) 
Repeated-measures ANOVA revealed a significant main effect of session (F (10, 
230) = 27.14, p < 0.001), main effect of lever (F (1, 23) = 67.44, p < 0.001; Figure 8D), 
and an interaction between session and lever (F (10, 229) = 26.98, p < 0.001) during 
extinction.  A post-hoc Holm-Sidak's multiple comparisons test showed that active lever 
presses were significantly higher than inactive lever presses during sessions 1-7 (all p < 
0.05), but not during sessions 8-10. 
Morphine-Induced Reinstatement (n = 23) 
One-way repeated measures ANOVA of reinstatement scores (responses on the 
active lever - inactive lever) during morphine-induced reinstatement showed an overall 
effect of treatment (F(1.12, 24.73) = 18.18, p < 0.001) (Figure 9A). Holm-Sidak’s multiple 
comparisons test revealed that the MOR + NO CUE, VEH + CUE and MOR + CUE 





condition (all t ≥ 4.82, all p < 0.001). MOR+CUE resulted in significantly higher 
responding than VEH + CUE (t = 3.83, p = 0.002) and MOR + NO CUE (t = 3.80, p = 
0.002). 
Stress-Induced Reinstatement (n = 22) 
 There was an overall effect of treatment on reinstatement scores during stress-
induced reinstatement (F(1.68, 35.35) = 8.92, p = 0.001) (Figure 9B). Holm-Sidak’s 
multiple comparisons test revealed that VEH + CUE (t = 5.98, p < 0.001) and YOH + CUE 
treatment (t = 3.75, p = 0.006) resulted in higher responding than the VEH + NO CUE 
control condition, whereas the YOH + NO CUE condition did not.  Responding during 
YOH + CUE reinstatement was significantly higher than during the YOH + NO CUE 
condition (t = 3.17, p = 0.02), but did not differ from the VEH + CUE condition. 
Correlations in the MOR + NX group 
 Composite z-scores for ICSS thresholds during precipitated withdrawal were 
significantly correlated with all individual measures: peak ICSS threshold (r = 0.92, p < 
0.001), average ICSS threshold (r = 0.86, p < 0.001) and degree of sensitization of WIA (r 
= 0.54, p = 0.003). This validates our use of z-scores to measure cumulative precipitated 
withdrawal severity (see Belin et al., 2009; Belin & Deroche-Gamonet, 2012). Pearson’s r 
revealed that greater composite WIA severity during precipitated withdrawal correlated 
with lower infusions during acquisition of MSA and higher elasticity of demand (i.e., lower 
reinforcing efficacy) (Table 4, Figure 10). Greater peak ICSS threshold elevation during 
spontaneous withdrawal was associated with lower acquisition and reinstatement induced 





elasticity of demand (p = 0.06, Figure 11). Most MSA measure correlated significantly 
with at least one other MSA measure (Table 4). However, no individual MSA measure 
correlated with as wide a range of other MSA measures as did WIA (Table 4).  
 
Figure 6. Mean (± SEM) ICSS thresholds (A) and response latencies (B) (expressed as 
percent of baseline) during naloxone-precipitated withdrawal (acute dependence). Mean (± 
SEM) ICSS thresholds (C) and latencies (D) as percent of baseline during spontaneous 
withdrawal (acute dependence).  *,** Different from SAL+SAL group at that session or 
SAL condition during hours 6-98 (main effect), p < 0.05, 0.01.  # Different from Session 1 







































































Figure 7: (A) Mean (± SEM) somatic signs in groups on the 5th day of acute dependence 
precipitated withdrawal testing. (B) Mean (± SEM) somatic signs in the MOR and SAL 
condition 26 hours after injection during acute dependence spontaneous withdrawal 
testing. *** Significant effect of group, p < 0.001.  * Different from SAL + SAL group or 



































Figure 8. MSA in MOR + NX rats. (A) Mean (± SEM) active and inactive lever presses 
and infusions during the first 10 sessions of acquisition. ** Different between active and 
inactive lever presses, p < 0.01. (B) Mean (± SEM) infusions at each FR during demand 
testing. ** Different compared to infusions at FR1, p < 0.01. (C) Exponential demand curve 
describing morphine consumption as a function of unit price for rats as a group, and for 
individual rats with relatively high (rat #26) and low (rat #9) elasticity of demand (α). (D) 
Mean (± SEM) infusions during baseline and during the first 10 extinction sessions, ** 
Different compared to pre-extinction (baseline), p < 0.01.  The increase in infusion rates 
during session 6 reflects spontaneous recovery following the weekend break in extinction 






















































Figure 9. Mean (± SEM) reinstatement scores (differences between active and inactive 
lever responses) during morphine- and cue-induced reinstatement (E) and yohimbine-and 
cue-induced reinstatement (F).  Active and inactive lever presses during each reinstatement 
















Figure 10: Scatterplots with regression line depicting the relationship between naloxone-
precipitated withdrawal measured using ICSS (composite z-score) and infusions during 
first 10 sessions of acquisition (A), log α (B), infusions during first 10 sessions of extinction 
(C), and reinstatement score during MOR + CUE (D), MOR + NO CUE (E) and YOH + 








Figure 11: Scatterplots with regression line depicting the relationship between peak 
spontaneous withdrawal during ICSS testing and infusions during first 10 sessions of 
acquisition (A), log  (B), infusions during first 10 sessions of extinction (C), and 
reinstatement score during MOR + CUE (D), MOR + NO CUE (E) and YOH + CUE (F) 















































































































Secondary correlations in the MOR + NX group 
 There were no significant correlations between any of the secondary predictors (i.e., 
somatic signs during acute dependence testing, locomotor activity) and any measure of 
MSA (all p-values > 0.05, data not shown).  
Locomotor activity and MSA in control groups 
 Rats in the control groups did not differ from the MOR + NX group in terms of 







 ICSS thresholds were significantly elevated during precipitated withdrawal during 
late-stage dependence (Figure S3), while somatic signs were significantly elevated during 
spontaneous withdrawal (Figure S3). However, these effects were not correlated with most 
MSA measures (see Supplementary Material). 
Attrition  
 Several animals (see Results for group size of the MOR + NX group during each 
phase of the MSA protocol) were lost to attrition during the course of the protocol due to 
loss of ICSS headcap, loss of stability of ICSS thresholds, failure to acquire MSA, loss of 
catheter patency, health issues, or other problem. Data for these animals are analyzed for 
those phases they completed.  
Baseline ICSS measures during acute dependence  
Baseline ICSS thresholds and response latencies did not differ between groups 
during either precipitated or spontaneous withdrawal testing during the acute dependence 
phase (Table S1). 
Locomotor activity  
One-way ANOVA on total distance travelled during the locomotor activity session 
in the MOR + NX and control groups (MOR + SAL, SAL + NX, SAL + SAL) indicated 
no effect of group (Fig S1A). An additional one-way ANOVA of within-session activity 
in the MOR + NX group indicated a main effect of time (F (3.417, 95.66) = 64.07, p < 
0.0001).  Activity levels were highest during the first 30 minutes of the 2-hour session (Fig 





al., 1989). Distance travelled did not correlate with any subsequent MSA measure (all p ≥ 
0.11).  
Comparison of MSA in the MOR + NX and control groups 
Rats in the MOR + NX group and control groups did not differ on most measures 
of MSA. Two-way repeated measures ANOVA on infusion rates between the MOR + NX 
and the control groups during the first 10 days of acquisition indicated a significant overall 
effect of session (F (9, 468) = 2.20, p = 0.02) but no effect of group or interaction between 
group and session (Figure S2A).  Two-way ANOVA on group and FR during demand 
testing showed a significant main effect of FR (F (6, 246) = 152, p < 0.001) and interaction 
between group and FR (F (18, 246) = 2.144, p = 0.005).  but no main effect of group (Figure 
S2B).   The MOR + NX had significantly lower infusions at FR 2 and FR 3 compared to 
the SAL + SAL group (all p < 0.01). However, a one-way ANOVA comparing elasticity 
of demand (α) (i.e., the primary outcome) indicated no significant difference between 
groups (Figure S2C). The MOR + NX and control groups also did not significantly differ 
in three secondary behavioral economic measures: intensity of demand (Q0), maximal 
response output (Omax) and the unit price at which maximal response output occurred (Pmax) 
(Table S2). Additionally, the groups did not differ in infusions during extinction, as a two-
way repeated measures ANOVA revealed a significant overall effect of session (F (10, 
410) = 79.53, p < 0.0001) (Figure S2D) but no effect of group or group x session 
interaction.  Finally, two-way ANOVAs showed a main effect of reinstatement condition 
on reinstatement scores during morphine- and cue-induced reinstatement (F (1.291, 51.65) 





22.68, P < 0.0001), with responses significantly elevated during all drug (morphine or 
yohimbine) and/or cue conditions compared to the VEH + CUE control condition (Figure 
S2E-F).  However, there was no significant main effect of group or interaction during either 
morphine- and cue-induced reinstatement testing or yohimbine- and cue-reinstatement 
testing.  
Additional behavioral economics measures 
Table S2 shows additional parameters from the exponential demand curve, 
However, these additional measures (Q0, Omax or Pmax) from demand testing did not 
significantly correlate with either ICSS thresholds or somatic withdrawal signs during 
naloxone-precipitated or spontaneous withdrawal in the Mor + NX group during the acute 
dependence phase.  
Late-stage dependence 
Precipitated withdrawal: ICSS 
 Baseline ICSS thresholds and response latencies for late-stage precipitated 
withdrawal did not differ between groups (Table S3). Two-way ANOVA on ICSS 
thresholds during precipitated withdrawal revealed a significant main effect of group (F (3, 
22) = 6.2, p = 0.003), but no significant effect of session or interaction. Holm-Sidak’s 
multiple comparison showed significantly higher ICSS thresholds in the MOR + NX group 
compared to the SAL + SAL control group during all sessions (all t(22) ≥ 3.71, all p < 
0.05) (Figure S3A).  There was no significant effect of group, session, or group x session 
interaction on ICSS latencies during precipitated withdrawal (data not shown).  





Baseline ICSS thresholds and response latencies did not differ between groups 
(Table S3). ICSS thresholds during hours 2 (agonist effect) and hours 6 – 98 (withdrawal 
period) of spontaneous withdrawal did not differ between the two groups receiving MOR 
(MOR + NX versus MOR + SAL groups) or SAL (SAL + SAL versus SAL + NX groups). 
Data from these groups were therefore combined into a single MOR (n = 15) and SAL (n 
= 5) group. Welch’s corrected t test showed no significant difference in ICSS thresholds 
between MOR (118.4 ± 14.03%) and SAL (102.6 ± 2.58%) groups during the 2-hour 
session, indicating an absence of effects of MOR itself on ICSS. Two-way ANOVA on 
ICSS thresholds during spontaneous withdrawal 6-98 hours after morphine injection 
revealed no significant main effect of time, group (morphine vs. saline) or interaction 
(Figure S3B). However, comparison of peak ICSS threshold values between 6 hours and 
98 hours (regardless of the time point at which they occurred) differed significantly 
between the morphine (121.7 ± 4.78%) and saline (106.8 ± 2.04%) groups (Welch-
corrected t(17.54) = 2.85, p = 0.01).  No significant difference in ICSS response latencies 
was observed between groups 2 hours after injection (agonist effect) or 6-98 hours after 
injection (withdrawal effect) (data not shown).  
Precipitated withdrawal: Somatic signs 
 One-way ANOVA revealed a significant overall difference in somatic signs scores 
between groups during the 5th session of precipitated withdrawal during late stage 
dependence (F(3, 23) = 4.57, p = 0.01). However, Dunnett’s multiple comparison indicated 
that none of the groups differed significantly from the SAL + SAL group (Figure S3C).  





 Somatic signs did not differ between the two groups receiving MOR or between 
the two groups receiving SAL. Data from these groups were therefore combined into single 
MOR (n = 15) and SAL (n = 5) conditions, respectively.  Total somatic signs in the MOR 
condition were significantly higher than in the SAL condition (Welch-corrected t(21.44) = 
2.19, p = 0.04) (Figure S3D). 
Correlations in the MOR + NX group during late-stage dependence 
ICSS thresholds or somatic signs scores during late-stage dependence during 
precipitated or spontaneous withdrawal did not correlate with any MSA measure, except 
for a significant correlation between higher composite z-score for ICSS thresholds during 
precipitated withdrawal and higher infusions during extinction (i.e., greater resistance to 
extinction; r = 0.61, p = 0.04). 
 Comparison of withdrawal severity during acute dependence and late-stage 
dependence in rats that completed both phases suggested that these measures were largely 
independent.  Thus, ICSS thresholds during precipitated or spontaneous withdrawal during 
late-stage dependence did not correlate with these same ICSS measures during acute 
dependence (all r: -0.16 ≤ r ≤ -0.04, all p ≥ 0.57).  Somatic signs during spontaneous 
withdrawal correlated significantly between late-stage dependence and acute dependence 
(r = 0.73, p = 0.007), but this correlation was not observed during precipitated withdrawal 































YOH +  
NO CUE 
1. Precip. WIA          
2. Spont. WIA .41*         
3. Acquisition -.39* -.55**        
4. Log α .43* .40 -.42*       
5. Extinction -.01 .-.26 .35 -.39      
6. MOR+CUE -.07 -.53** .15 -.13 .20     
7. MOR + NO CUE -.21 -.63** .33 -.21 .35 .81***    
8. YOH + CUE -.32 -.17 .18 -.57** .35 -.13 -.05   
9. YOH + NO CUE .11 .04 -.12 -.26 -.20 -.16 -.26 .61**  
10. VEH+ CUE -.17 -.06 .16 -
.66*** 
.38* -.10 -.11 .77*** .59** 
 
Correlation between ICSS withdrawal measures and MSA measures (Pearson’s R) in the Mor + NX group. 1. Standardized composite 
score of average WIA, peak WIA, and degree of sensitization of WIA during naloxone-precipitated withdrawal. 2. Peak ICSS threshold 
during spontaneous withdrawal. 3. Average infusions during first 10 days of acquisition. 4. Log-transformed elasticity of demand 
computed from exponential demand model. Higher log α =  lower reinforcement efficacy. 5. Average infusions during first 10 days of 
extinction; 6.-10. Reinstatement score (active – inactive lever pressing) during reinstatement induced by morphine with cue 
(MOR+CUE), morphine with no cue (MOR+ NO CUE), yohimbine with cue (YOH+CUE), yohimbine with no cue (YOH+ NO CUE) 








 Greater WIA during antagonist-precipitated and spontaneous withdrawal in an 
acute dependence model was associated with lower vulnerability on multiple measures of 
subsequent i.v. MSA (e.g., elasticity of demand, reinstatement). In fact, WIA predicted a 
wider range of MSA measures than did any individual measure of MSA. These findings 
are consistent with the principle that initial drug sensitivity is an important predictor of 
subsequent drug use (Deminiere et al., 1989; Chappell & Weiner, 2008; Nishida et al., 
2016), and also support the notion that drug withdrawal sensitivity may be protective 
against drug addiction (Carroll et al., 2008; Holtz et al., 2015; Radke et al., 2015). In 
particular, our findings with outbred rats complement findings of lower WIA in rats bred 
for high saccharin consumption (Holtz et al., 2015), a line that exhibits greater SA of 
opioids and other drugs (Carroll et al., 2002). Together, these data identify WIA as a 
potential target for understanding behavioral and neurobiological mechanisms underlying 
the emergence of opioid addiction.  
Several features of WIA during acute dependence distinguish it from other 
behavioral measures of vulnerability to addiction-like behaviors.  First WIA is unique in 
that it reliably predicts individual differences in opioid SA in outbred rats, whereas 
numerous established behavioral markers of individual differences in stimulant and alcohol 
SA (e.g., sensation-seeking as measured by open-field locomotor activity, impulsivity) do 
not (Study 1; Dileen et al., 2012; McNamara et al., 2010).  Indeed, open-field activity was 
not correlated with any measure of MSA in this study (see Supplementary Material), 





WIA also differs from other behavioral predictors of SA of other drugs in that it predicted 
a variety of measures of SA (Belin et al., 2016). An additional unique feature of WIA is 
that it is an outcome of early opioid exposure, as opposed to a preexisting disposition. 
Therefore, WIA may represent a neuroadaptive mechanism underlying addiction 
vulnerability, as opposed to only a behavioral indicator. As such, WIA promises to provide 
unique information on addiction vulnerability to complement findings obtained using 
existing behavioral markers of addiction vulnerability. 
 In contrast to WIA, somatic signs during acute dependence did not predict any 
primary MSA measure. These data complement previous findings indicating that 
affective/emotional and somatic withdrawal signs are mediated by distinct neurobiological 
mechanisms (Koob & Le Moal, 1997; Nestler & Carlezon, 2006), and supports the notion 
that the former have greater relevance to addiction vulnerability (Schulteis et al., 1994; 
Baker et al., 2004; Koob & Le Moal, 2005). 
The current findings contrast with some studies reporting a positive relationship 
between withdrawal sensitivity and addiction vulnerability (Ahmed et al., 2002; Kenny et 
al., 2006; Funk et al., 2006). Numerous methodological differences between studies could 
account for this discrepancy (e.g., drug class studied, etc). In addition, the current acute 
dependence model isolates the earliest stages of dependence, while prior studies involved 
subjects in which dependence had already been established. As such, withdrawal sensitivity 
may shift from being a protective factor to a vulnerability factor for addiction as 
dependence develops (Kiluk et al., 2019). The fact that WIA during late stage dependence 





consistent with this possibility. The lack of correlation between WIA during acute 
dependence and late-stage dependence (Supplementary Material) also suggests that each 
of these stages may provide unique information. Use of larger group sizes in order to 
provide adequate statistical power is needed to further address this issue, which was not a 
primary goal of this study.  
 Comparison of locomotor activity and MSA in the MOR + NX and control groups 
suggests that a history of morphine exposure and/or withdrawal had limited or no effects 
on these measures. The MSA data contrast with findings that repeated, experimenter-
administered acute drug injections (and presumably spontaneous withdrawal episodes) can 
enhance subsequent drug SA (Piazza et al., 1989; Mendrek et al., 1998; Shoaib et al., 1997).   
Methodological differences across studies (e.g., types of drugs, duration of interval 
between the final acute injection and onset of SA) may account for the similar MSA across 
groups in this study.  Importantly, results from this secondary comparison do not impact 
interpretation of the correlations between WIA and measures of MSA in the Mor + NX 
group, which was our primary outcome. 
Behavioral economics has been useful for understanding individual differences in 
addiction vulnerability in both humans and animals (Chase et al., 2013; Worley et al., 2015; 
Diergaarde et al., 2008; Grebenstein et al., 2013; Hursh & Silberberg, 2008; LeSage et al., 
2016), but has not been applied extensively to MSA. Consistent with Study 1, an 
exponential demand function generally provided a good fit for morphine consumption 
under an FR escalation procedure. There were also considerable individual differences in 





withdrawal, and a similar trend was observed for spontaneous withdrawal.  Together, these 
data further support the utility and sensitivity of behavioral economics to study individual 
differences in opioid addiction vulnerability. 
A potential limitation of this study is that all rats underwent the experimental phases 
in a fixed order.  It could therefore be argued that the relationships we observed were due 
to the order in which the measures were assessed, rather than their relationship per se.  It 
is important to note that not all aspects of the protocol were fixed, as order of reinstatement 
conditions (drug + cue, cue alone, etc) within each reinstatement phase (morphine/cue, 
yohimbine/cue) were counterbalanced across rats.  In addition, the current order of phases 
was to some extent unavoidable due to the goals of the study (e.g., assessment of acute 
dependence prior to MSA) or to the required procedure for assessing certain MSA 
measures (e.g., testing extinction of MSA prior to reinstatement).  Also, it was prudent to 
test yohimbine-induced reinstatement as the final MSA measure because of the well-
established long-term effects of yohimbine or other stressors on behavior, including drug 
sensitivity (Ball et al., 2015; Barsy et al., 2011; Pizzimenti et al., 2017).   Nonetheless, we 
cannot rule out the possibility that the relationships observed here were specific to this 
order of experimental phases.  However, even such an order effect would not negate the 
utility of the current procedure.   
 In conclusion, this study establishes WIA as one of the first behavioral measures to 
reliably predict individual differences in future opioid SA.  Evaluating the generality of the 
current findings to other subject variables (e.g., genetic background using inbred rat 





anhedonia such as sucrose preference, or other negative affective withdrawal signs such as 
elevated startle responding) will be an important direction for future research. Given the 
numerous sex differences in addiction vulnerability reported in both humans and animals 
(Back et al., 2011; Becker & Koob, 2016; Becker et al., 2017), evaluating effects of sex in 
this model is also of interest.  Furthermore, measures of opioid SA that model other aspects 
of addiction (e.g., escalation of SA under extended access conditions, a model of 
compulsive drug use,) are also an important direction for future research.  Finally, 
characterizing the neurobiological mechanisms underlying WIA will allow addiction-
related effects (i.e., those uniquely related to severity of WIA) to be differentiated from 
other, corollary effects of opioids.  Hence, further use of this model promises to provide 
novel insights into neurobiological mechanisms underlying vulnerability and/or resilience 























Chapter 4: Individual Differences in Different Measures of Opioid Self-
administration in Rats Are Accounted for by A Single Latent Variable 
Introduction 
 Individual differences in susceptibility to addiction in humans have been studied 
widely through factor analysis, a statistical method that identifies “latent” variables 
(variables that are not measured directly) that reflect the common variance among a larger 
number of related measures. These models provide both insights into the relationship 
between different facets of addiction- and dependence-related symptomatology (Gillespie 
et al. 2007), and a relatively parsimonious account of disease comorbidity (Neale & 
Kendler, 1995). For example, factor analytic approaches have revealed that liability to 
alcohol abuse is associated both with a general drug abuse vulnerability factor and with 
several factors that are specific to this form of addiction (e.g., genetic variants in alcohol 
metabolizing enzymes) (Krueger et al., 2002; Tsuang et al., 1998; Luczak et al., 2006).  
 Factor analytic approaches have been widely used in the clinical literature to 
explore the factor structure underlying various addiction measures. Such structures may 
have both vertical and horizontal dimensions. The vertical dimension essentially represents 
hierarchical relationships between concrete traits or measures and higher-order, more 
abstract, or general “latent” factors. The horizontal dimension represents the degree of 
similarity between factors within a single level of the hierarchy (Goldberg & Velicer, 
2006). Elaboration of such two-dimensional factor structure may yield one or more robust 
endophenotypes that can be used to identify genomic loci associated with core features of 





In animal addiction research, factor analytic approaches could be useful in identifying the 
underlying associations between, and uniqueness of, different addiction-related behavioral 
measures, developing more reliable measures of addiction, and uncovering their underlying 
genomic and neurobiological substrates (see Chapter 1). Factor analytic approaches have 
rarely been employed in this area, however, despite the fact that the drug self-
administration (SA) paradigm models a variety of aspects of addiction (e.g., acquisition, 
relapse, etc.) within individual subjects, thereby lending itself to multivariate statistical 
analyses. In one previous study, an exploratory factor analysis revealed three addiction 
vulnerability measures – (a) SA despite punishment, (b) progressive ratio (PR) breakpoint, 
and (c) drug-seeking during no-drug periods – as loading onto a single latent factor 
underlying cocaine SA in rats, whereas extinction loaded onto a separate factor (Deroche-
Gamonet et al., 2004). Nevertheless, there has yet been any preclinical SA study to test 
how well drug SA data fit any hypothesized factor structure. Moreover, despite the 
dramatic impact of opioid addiction on public health (Center for Behavioral Health 
Statistics and Quality, 2020), no preclinical studies have applied FA to opioid SA. 
 The primary goal of this study was to use FA to examine the latent factor structure 
between four measures of i.v. opioid SA in rats (e.g., acquisition, demand elasticity, 
morphine/cue-induced reinstatement, stress/cue-induced reinstatement), using data from 
Study 2. The four SA measures were selected due to their common use in preclinical studies 
and to the relevance of each to different aspects of addiction (Belin et al., 2008; Banna et 





 In animal research, there is frequently the implicit assumption that a variety of SA 
variables all have relevance to addiction vulnerability. This is consistent with findings in 
humans showing that individual differences in multiple measures of abuse liability are best 
accounted for by a single latent factor (Blanco et al., 2013; Lennox et al., 2006; Lynskey 
& Agrawal, 2007). Therefore, in the current study, a one-factor model was fitted to the 
data, with the single latent factor conceptualized as the “addiction” factor.  
 It has been proposed that minimum sample size required for a factor analysis ranges 
between N = 50-250 (de Winter & Dodou, 2012; Cattell, 1978; Gorsuch, 1983; Guilford, 
1954; Kline, 1979). Conducting small sample size FA might result in many issues that are 
otherwise uncommon in large sample size analyses, such as Heywood cases denoting 
negative estimated variances (de Winter & Dodou, 2012; Cooperman & Waller, 2021). 
Preclinical addiction studies have typically employed relatively small sample sizes, which 
pose a challenge to the use of FA. The secondary goal of the current study was to test the 
utility of a novel approach to conducting FA on preclinical data that allows for smaller 
sample sizes to be used. Several proposed (Jacobucci et al., 2016; Jung & Takane, 2007; 
Jung & Lee, 2011) “regularization methods” can effectively address the challenges of 
conducting small sample FA by reducing the number of estimated model parameters. In 
this study, we utilized two robust regularization methods in conjunction with a method to 
obtain a robust correlation matrix from our data (Rousseeuw & Driessen, 1999) to 
demonstrate the feasibility of conducting FA in a small preclinical dataset. By applying 
these iterative statistical procedures to our data, we aimed to understand the core 





Materials and Methods 
Overview of experimental protocol 
 Data from Study 2 were used for the current analyses. Male Sprague-Dawley rats 
were first trained in an intracranial self-stimulation (ICSS) paradigm and then underwent 
naloxone-precipitated and/or spontaneous withdrawal from acute morphine injections or 
received control (saline) injections. During the subsequent MSA protocol, all rats first 
acquired MSA, then underwent demand testing in which the fixed ratio (FR) response 
requirement was progressively increased. Rats then re-acquired and subsequently 
underwent extinction of MSA. After extinction, rats were tested for drug-induced 
reinstatement (with morphine injection prior to the SA session) and finally, stress-induced 
reinstatement (with injection of the pharmacological stressor yohimbine prior to the SA 
session), both in the presence and absence of the visual cue paired with morphine, and with 
appropriate within-subject control conditions (see Chapter 2 for more details on animals, 
apparatus and experimental protocol). Since a history of morphine and/or naloxone 
injections during ICSS testing did not have a significant effect on subsequent MSA, rats 
from all groups that completed all phases of the study were included in the data analyses 
(N = 43).  
Overview of factor model 
 We tested a one-factor model with one latent variable (the “addiction” factor) and 
four observed variables from the MSA model: acquisition, elasticity of demand (), and 
morphine/cue- and stress/cue-induced reinstatement with visual cue light present.   These 





thought to capture and their common application in drug SA research.  Acquisition was 
defined as the average number of infusions across the first 10 days of MSA. An exponential 
demand function was fitted to data from the FR escalation protocol to obtain the α statistic, 
as described in Studies 1 & 2. α refers to the rate of change in consumption with increases 
in unit price (elasticity of demand), with higher α values indicating lower reinforcement 
efficacy.  Reinstatement was measured as the difference between the number of active and 
inactive lever presses over each of the 2-hr reinstatement test sessions after the challenge 
(i.e., morphine or yohimbine) drug injection, with cue light present.  These reinstatement 
conditions were analyzed because they produced more robust reinstatement than either the 
challenge drug (morphine or yohimbine) alone or the cue alone (see Fig 12C and 12D). A 
higher number of infusions during acquisition, lower elasticity of demand (α), and higher 
reinstatement scores reflect greater abuse liability for each of these measures.   
Statistical analyses  
 All statistical analyses were performed in GraphPad Prism (GraphPad Software, 
San Diego, California USA) and R ver. 4.0.4 (R Core Team, 2021). A one-factor model 
was hypothesized to show good model-fit with each of the SA measures showing high 
factor loadings, indicating a common “addiction” factor underlying all tested SA measures.  
 Three distinct methods were used for extracting factor loadings. Given the small 
sample size of our data set and the several outlying values (to be discussed later), we used 
two distinct factor extraction algorithms that are known to yield robust factor loadings in 
small sets of non-normal data. The first method involves computing Mahalanobis distances 





chi-squared tests (α = 0.1). Next, we used the minimum covariance determinant (MCD: 
MASS package; Venables & Ripley, 2002; Rousseeuw & Driessen, 1999) method to 
produce a robust estimator of multivariate scatter and center to remove the multivariate 
outliers and generate a robust correlation matrix. This robust correlation matrix was factor 
analyzed with a regularized least squares estimator (fareg function; Waller, 2020). Robust 
least squares estimation does not assume data multinormality and aims to minimize 
residuals between the observed and reproduced correlations under the proposed factor 
model (Beauducel & Herzberg, 2006). Model fit was tested via the correlation root mean 
square residual (CRMR) statistic: 
𝐶𝑅𝑀𝑅 =  
1
𝑡 − 𝑝
(𝜌 −  𝜌 )  , 
with t denoting the number of nonredundant population variances and covariances among 
the p observed variables, 𝜌  denoting the correlation between variables i and j, and 𝜌  
denoting the model implied population correlation under the theoretical model (Maydeu-
Olivares, Shi & Rosseel, 2018). CRMR is commonly used in FA and structural equation 
modeling (SEM) as a model fit statistic, with smaller numbers indicating better model fit. 
Finally, effect size of overall model misfit was determined by the 1 statistic, defined as 




where  denotes a population covariance matrix, Σ  denotes the population covariance 
under the null hypothesis, and tr denotes the trace operator (the trace of a square matrix 





 The second robust method for analyzing the data used regularized factor analysis 
as described by Jung and colleagues (Jung & Takane, 2007; Jung & Lee, 2011; these 
methods are implemented in the fareg function; Waller, 2020). Both least squares (LS) and 
maximum likelihood (MLE) regularized FA were used to estimate robust factor loadings 
for testing the 1-factor model. Previous work suggests that these methods work extremely 
well in small samples of nonnormally distributed data (Copperman & Waller, 2021; Jung 
& Takane, 2007; Jung & Lee, 2011) and thus were deemed ideal for the current study. 
 To further demonstrate the advantages of the robust correlation and robust factor 
analytic methods, a third analysis was implemented using principal axis factoring, a 
traditional factor extraction method, with the complete data set of 43 rats (using the faMain 
function in the R fungible library; Waller, 2020). This method was not expected to perform 
well given the small sample size of our data set and the existence of several multivariate 
outliers. To allow comparison with the other analyses, we also computed the CRMR index 
for this analysis.  
Results 
MSA 
 Detailed behavioral results from the MSA protocol are reported in Study 2.  Briefly, 
rats reliably acquired MSA, exhibiting a clear preference for the active over inactive 
response lever (Fig 12A).  Increases in FR requirement resulted in a progressive reduction 
in morphine consumption that was well-described by an exponential demand function (R2 
= 0.84) (12B). After MSA reacquisition and extinction in the absence of the morphine-





dose of morphine in the absence of the cue light (MOR + NO CUE; 12C), response-
contingent presentation of the cue light (VEH + CUE), or combined exposure to morphine 
and the cue light (MOR + CUE). Similar findings were observed when reinstatement was 
induced by the pharmacological stressor yohimbine (12D).  
FA 
 Each variable was standardized to keep their scales consistent. The factor loadings 
from each analysis are shown in Table 4.  
 For the two regularized FA analyses, 5 multivariate outliers (α = 0.1) were 
identified from the chi-squared test using Mahalanobis distance. Subsequently, these 5 
multivariate outliers were excluded from the robust correlation matrix computation using 
MCD (Rousseeuw & Driessen, 1999). Using the robust correlation matrix with LS 
estimation, the first regularized FA revealed that acquisition, elasticity of demand and 
morphine/cue-induced reinstatement showed high factor loadings (all |loadings| ≥ 0.58) on 
a single common factor whereas stress/cue-induced reinstatement showed low factor 
loading on this dimension (loading = 0.27) (Table 5). The second regularized FA using 
MLE factoring (on the same robust correlation matrix) produced similar results. 
Acquisition, elasticity of demand and morphine/cue-induced reinstatement showed high 
factor loadings on a single dimension (all |loadings| ≥  0.59), and stress/cue-induced 
reinstatement again showed a low factor loading (loading = 0.28) (Table 5). Overall, based 
on the CRMR and Γ_1 values, the one-factor model showed excellent model fit (CRMR = 






Figure 12. Active and inactive lever pressing during acquisition (n = 43) (A); exponential 
demand curve for morphine intake during demand testing (n = 42) (B); difference scores 
between active and inactive lever pressing during morphine-induced (n = 43) (C) and 
yohimbine-induced (n = 43) reinstatement (D).  MOR = morphine. YOH = Yohimbine. 
VEH = Vehicle. Data points represent mean ± SEM.  *: significant difference compared to 











 Factor Loadings 
SA Measures Robust LS  Robust MLE Principal Axis 
Acquisition 0.58 0.59 0.48 
Demand -0.63 -0.64 -1.03 
Morphine/cue-induced reinstatement 0.62 0.63 0.32 
Stress/cue-induced reinstatement 0.27 0.28 0.27 
 
Estimates for factor loadings from 3 independent analyses. Robust LS: regularized FA using least squares estimates with MCD robust 
correlation matrix excluding 5 multivariate outliers; robust MLE: regularized FA using maximum likelihood estimates with robust 






 Our data demonstrated that a single latent Addiction factor fits four distinct 
morphine SA measures. This indicates that acquisition, elasticity of demand, 
morphine/cue-induced reinstatement, and stress/cue-induced reinstatement all in some way 
measure a common construct, akin to a general factor of addiction vulnerability. These 
findings support the implicit assumption in the preclinical literature that these different SA 
measures are related to abuse liability. This one-factor model is consistent with the clinical 
literature that also posits a single latent factor to underlie multiple measures of addiction 
(Blanco et al., 2013; Lennox et al., 2006; Lynskey & Agrawal, 2007).  
 In terms of individual factor loadings, results from both regularized FAs implicated 
elasticity of demand as the variable most reliably strongly associated with the Addiction 
factor, with a stable, high factor loading across both analyses. Previous studies have 
demonstrated the value of behavioral economics in studying individual differences in 
opioid addiction vulnerability in both humans and animals (Worley et al., 2015; Study 1 & 
2), and the high factor loading from our results further demonstrates the utility of this 
demand function.  
 In contrast, stress/cue-induced reinstatement did not load onto the Addiction factor. 
This means that although this factor underlies the four SA measures overall, other, unique 
factors likely contribute more strongly to individual differences in levels of stress/cue-
induced reinstatement than to the other three SA measures. The unique factor in this case 
may be the influence of stress itself. While activation of stress systems contributes to 





Piazza & Le Moal, 1998; Shaham et al., 1992), individual differences in sensitivity to stress 
(e.g., conferred by polymorphisms of the corticotropin releasing factor (CRF)1 receptor or 
CRF binding protein (Hansson et al., 2016; Treutlein et al., 2006) may well have their 
largest impact on stress/cue-induced reinstatement (George & Koob, 2010).   
 Utilizing different regularized FA methods with robust correlations in direct 
comparison with a traditional principal axis factoring method, we have demonstrated the 
feasibility of these statistical tools in analyzing sample sizes that are realistic targets for 
preclinical studies where traditional factor analysis methods might fail. These methods help 
address some major statistical challenges in small sample size factor analyses such as 
Heywood cases, which was observed using the traditional factor extraction method 
(Heywood, 1931; Kolenikov & Bollen, 2012).  Moreover, the regularization methods used 
in the current study have been shown to provide good recovery of underlying factor 
structures in simulation data, increasing confidence in the interpretation of our results (Jung 
& Takane, 2007; Jung & Lee, 2011).   
 Though statistical methods such as regularization enable complex multivariate 
analyses of small sample sizes, there are inherent limitations of such analyses, such as 
sampling bias, that could not be fully addressed in this study. Future studies could include 
a larger preclinical sample for analyses where cross-validation is warranted, such as 
regularized factor analytic methods using least absolute shrinkage and selection operator 
(LASSO) penalization (Jacobucci et al., 2016; Tibshirani, 1996). Additionally, with a 
larger preclinical sample, a higher count of observed variables could be included in the 





 A further limitation of this study is that some rats had prior morphine and/or 
naloxone experience, and all rats underwent ICSS surgery and training. However, no 
significant difference was found on any SA measure between rats with morphine and/or 
naloxone experience compared to saline controls.  Furthermore, despite their history of 
ICSS testing, rats from the current study showed similar acquisition and demand compared 
to rats from a previous study that did not have a history of ICSS testing (Studies 1& 2). 
Notwithstanding these limitations, the current study represents a first step in using FA to 
understand the factor structure of opioid SA.   
 Overall, this study identifies a single factor that contributes to four common opioid 
SA measures, revealing the common and unique information each of the measures could 
contribute to preclinical addiction literature. Elasticity of demand most reliably represents 
the common “addiction” factor while stress/cue-induced reinstatement provides 
information about constructs other than the common factor tested in this model. Therefore, 
future studies examining individual differences in opioid SA may be rendered most 
informative by selectively examining demand and stress/cue-induced reinstatement. More 
generally, exploring relationships beyond prevailing bivariate correlations in preclinical 
behavioral studies may further our understanding of addiction vulnerability and its 













Chapter 5: Summary and Overall Conclusions 
 Among all individuals who experiment with opioids, only a small subset develops 
opioid addiction. Furthermore, once acquired, the severity of addiction varies considerably 
between individuals (American Psychiatric Association, 2013; Belin et al., 2016; Vowles 
et al., 2015). Insight into the behavioral predictors of individual differences in the 
vulnerability to opioid addiction and the severity of addiction once acquired could help 
uncover psychological, neurobiological, and genetic factors contributing to opioid 
addiction, and could be key to developing effective preventions and treatments.  
How Do We Identify Behavioral Predictors of Individual Differences in Opioid 
Addiction Vulnerability? 
 Despite the importance of identifying behavioral predictors of individual 
differences in opioid addiction vulnerability, very few behavioral predictors of opioid SA 
have been established in preclinical research. In this dissertation, we utilized several unique 
approaches to evaluate several potential behavioral predictors of opioid SA in rats.  
Approach #1:  Evaluate Behavioral Predictors of Individual Differences in 
Addiction to Other Drugs of Abuse 
 A logical starting point in identifying predictors of opioid SA is to evaluate 
predictors of SA of other drugs of abuse (e.g. cocaine) (Belin et al., 2011; Belin et al., 2016; 
Suto et al., 2001; Turner et al., 2008; Piazza et al., 2000).  To this end, Study 1 evaluated 
the ability of spontaneous locomotor activity, which predicts SA of stimulants such as 
cocaine, to predict opioid SA. Contrary to our hypothesis, spontaneous locomotor activity 





complement previous preclinical studies showing that impulsivity, another reliable 
behavioral predictor of SA of other drugs, did not predict opioid SA (McNamara et al., 
2010). Together, these findings support the notion that distinct factors may contribute to 
individual differences in opioid addiction compared to other drugs of abuse. Previous 
research has shown many differences between the neurobiological mechanisms between 
drugs such as psychostimulants and opioids. For example, most neurons in the medial 
prefrontal cortex and the nucleus accumbens encode rewarding effects of either heroin 
cocaine, instead of both (Badiani et al., 2011; Ettenberg et al., 1982; Pettit et al.,1984; 
Chang et al., 1998). Such differences could potentially account for the unique predictors of 
SA of opioids versus psychostimulants.    
Approach #2: Evaluate Novel Predictors of Individual Differences in Opioid 
Addiction Vulnerability, Including Those Related to Opioid Exposure Itself 
The findings of Study 1 suggested the need for other approaches for identifying 
behavioral predictors of opioid SA. Sensitivity to the acute drug effects can be an important 
predictor of drug addiction in human literature, and sensitivity to the analgesic effects of 
opioids is one of the few behavioral measures shown to predict opioid SA in rats (DiFranza 
et al., 2007; O’Loughlin et al., 2003; Schuckit et al., 2004; Nishida et al., 2016).  Therefore, 
we evaluated whether another consequence of acute opioid exposure – anhedonia during 
withdrawal – could also predict opioid SA. Results of this study revealed a negative 
relationship between withdrawal-induced anhedonia (WIA) during initial morphine 





WIA as one of the very few behavioral predictors identified in the context of opioid SA 
(Nishida et al., 2016; McNamara et al., 2010; Study 2).  
Given that opioid withdrawal includes a variety of symptoms, it is possible that not 
all withdrawal sensitivity symptoms could be protective against opioid addiction. In Study 
2, somatic signs of withdrawal did not predict subsequent morphine SA, which suggests 
that affective withdrawal could be more relevant to opioid addiction vulnerability. 
However, other affective withdrawal symptoms, such as anxiety, might play a different 
role in opioid addiction vulnerability compared to initial WIA. This idea is supported by 
previous research showing that saccharin-preferring (higher propensity to drug SA) rats 
exhibited lower anhedonia but higher anxiety during drug withdrawal (Holtz et al., 2015; 
Radke et al., 2013).  
Approach 3:  Evaluate Vulnerability to Distinct Stages of Opioid Addiction 
 Since different measures of opioid SA each model a unique aspect of opioid 
addiction, it could be worthwhile to further investigate how each stage of opioid SA differs, 
as well as the factors contributing to individual differences to each stages of opioid SA. 
Study 2 provided some initial insight into the distinct stages of morphine SA by showing 
that WIA during naloxone-precipitated withdrawal and spontaneous withdrawal each 
predicted some but not all stages of morphine SA. Additionally, Study 3 revealed that 
despite being described by a common latent Addiction factor, acquisition, elasticity of 
demand, morphine-induced reinstatement and stress-induced reinstatement all had a large 
proportion of their variability not accounted for by the Addiction factor. The idea of distinct 





found that measures such as cue-induced reinstatement and extinction did not relate to the 
same underlying factors as other SA measures in those studies did (Flagel et al., 2016; 
Deroche-Gamonet et al., 2004). Further research into these unique stages of opioid SA 
could provide valuable information for prevention and treatment development for targeted 
behaviors (e.g., early-stage addiction or stress-induced relapse behavior).  
Approach 4:  Establish Reliable and Valid Measures to Study Opioid Addiction 
Vulnerability 
 In order to understand both the common and unique predictors of individual aspects 
of opioid addiction behavior, it is vital to establish a solid foundation for modeling these 
behaviors in preclinical research. The flexibility of the SA paradigm allows a diverse array 
of addiction-related behavior to be measured with a wide range of behavioral measures, 
but at the same time makes it difficult to determine which behaviors to model, or how to 
measure those behaviors. Multivariate statistical methods, including the FA utilized in 
Study 3, can help address this issue by providing insight on both how various measures 
relate to each other, as well as how they represent underlying constructs such as addiction. 
Moreover, to increase replicability of preclinical findings and choose the ideal SA 
measures for each study, it could be beneficial to examine the reliability of each SA 
measure (e.g., how a measure performs across different experiments).  
 One reliable SA measure identified in the current studies in elasticity of demand as 
determined using behavioral economics. The exponential demand function described 
morphine consumption well regardless of whether unit price was manipulated via 





measures (α, Q0, etc.) from the behavioral economics model all showed significant 
between-subject variability in Study 1 and Study 2, making them suitable for individual 
differences research. Finally, among the measures included in the one-factor model in the 
FA, elasticity of demand reliably loaded closely to the Addiction factor in both regularized 
analyses, making it a good indicator of the latent Addiction factor. Additionally, other 
studies have shown the feasibility of using behavioral economics to measure reinforcing 
efficacy of other opioids in animals as well as reinforcing efficacy of opioids in humans 
(Worley et al., 2015; Stafford et al., 2019; Strickland et al., 2019). As such, behavioral 
economics could therefore not only be a reliable measure to use with the SA paradigm in 
rats, but also a bridge to narrow the gap between preclinical and clinical studies.   
Approach #5:  Evaluate the Feasibility of Using Novel Statistical Techniques to 
Study Opioid Addiction Vulnerability in Small Samples 
 FA has been used frequently in clinical addiction research involving large sample 
sizes. However, sample sizes comparable to those typically used in clinical research are 
often difficult to accomplish in preclinical studies. The small sample size in typical 
preclinical behavioral studies poses many challenges that novel statistical methods aim to 
address, as demonstrated by the comparison between a traditional factor extraction method 
and robust FAs in Study 3. The traditional principal axis factor extraction method produced 
a Heywood case, an error many small sample size analyses run into where an impossible 
solution such as negative variance was found. In contrast, the two regularized FA methods 
with robust correlation matrices successfully estimated factor loadings for each SA 





limitations with small sample size analyses, preclinical studies on individual differences in 
opioid addiction vulnerability could also start exploring complex multivariate relationships 
within the SA paradigm, potential latent factors underlying opioid addiction vulnerability, 
and eventually behavioral predictors of these latent factors.    
Additional Future Directions 
 Findings from studies described in this dissertation raise many additional research 
questions to be addressed in future studies. The role of WIA during initial opioid exposure 
has been established in this dissertation in male rats only. Nevertheless, women can 
develop addiction to opioids and other drugs more rapidly and relapse more easily than 
men, and females can be more vulnerable to addiction-related effects of drugs of addiction 
compared to males in preclinical models (Lynch et al., 2002; Hernandez-Avila et al., 2004; 
Husky et al., 2008). Therefore, examining the ability of WIA to predict opioid SA in 
females could help uncover the common and unique mechanisms underlying opioid 
addiction vulnerability in males and females.  
 To further understand the differences between the role of sensation-seeking in 
addiction to opioids versus other drugs, future studies could focus on more direct 
comparisons using SA of both opioids and other drugs within the same animals, and to 
examine individual differences in neurobiological pathways that are uniquely impacted by 
each drug (Badiani et al., 2011). Moreover, it could be beneficial to explore the similarities 
and differences in mechanisms underlying stress-induced reinstatement and other, similar 
SA measures, such as morphine-induced reinstatement. Understanding the mechanisms for 





behavior and subsequently shed light on effective preventions for relapse. Finally, continue 
employing multivariate statistics and refining analytical methods for small sample size 
analysis could shed light on more complex relationships between behavioral predictors, 
SA measures and underlying latent factors related to opioid addiction, and eventually lead 
to better understanding of mechanisms contributing to opioid addiction vulnerability.  
Final Conclusions 
 Overall, these studies extend the opioid individual differences literature by 1) 
showing that locomotor activity, a reliable predictor of SA of other drugs of abuse, does 
not predict opioid SA, 2) identifying WIA during initial drug exposure as a reliable 
predictor of opioid SA, and 3) applying FA and statistical methods appropriate for small 
sample size preclinical studies to opioid SA data. Future preclinical studies could benefit 
not only from examining behavioral predictors more relevant to opioid addiction 
vulnerability such as initial WIA, but also from identifying reliable and valid measures of 
opioid addiction behaviors such as elasticity of demand under the SA paradigm. 
Understanding factors contributing to individual differences in opioid addiction 
vulnerability could eventually lead to the development of better preventions and treatments 
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Appendix: Supplemental Materials (Study 2) 
ICSS 
Apparatus 
Rats were tested in operant conditioning chambers (29×26×33 cm; Med Associates, 
St. Albans, VT, USA) placed inside sound-attenuating cubicles. A 5-cm-wide metal wheel 
manipulandum was fixed to the front wall. Brain stimulation was administered with 
constant current stimulators (model #PHM-152, Med Associates). Rats were connected to 
the stimulation circuit through bipolar leads (Plastics One, Roanoke, VA, USA) attached 
to gold-contact swivel commutators (Plastics One). MED-PC IV software was used to 
control stimulation parameters and for data collection. 
Surgery 
Animals were anesthetized with ketamine (75 mg/kg, i.m.) and dexmedetomidine 
(0.5 mg, i.m.) and implanted with a bipolar stainless-steel electrode (Plastics One) in the 
medial forebrain bundle at the level of the lateral hypothalamus as described in Roiko et 
al. (2009). Animals were allowed to recover for at least 1 week prior to ICSS training. 
During the first 2 days of recovery, all animals received injections of the antibiotic 
ceftriaxone (5.25 mg, i.m.) and the analgesic buprenorphine (0.1 mg/kg, s.c.). 
General Testing Procedures 
ICSS. Each trial was initiated with presentation of a non-contingent stimulus (0.1-
ms cathodal square wave pulses at a frequency of 100 Hz for 500 ms) followed by a 7.5-s 
window, during which a positive response on the wheel manipulandum produced a second 
contingent stimulation identical to the first. Lack of responding during the 7.5-s window 





variable inter-trial interval averaging 10 s (range, 7.5–12.5 s), during which time additional 
responses delayed the onset of the subsequent trial by 12.5 s. Stimulus intensities were 
presented in four alternating descending and ascending series (step size, 5 μA), with five 
trials presented at each current intensity step. The current threshold for each series was 
defined as the midpoint between two consecutive intensity steps that yielded three or more 
positive responses and two consecutive intensity steps that yielded three or more negative 
responses. The overall ICSS threshold for the session was defined as the mean of the 
current thresholds from the four alternating series. To assess performance effects (e.g., 
motor disruption), response latencies (time between onset of the non-contingent stimulus 
and a positive response) were averaged across all trials in which a positive response was 
made. 
 Somatic withdrawal signs.  Rats were placed in a clear plastic circular chamber and 
recorded with a digital camera for 10 min. Recordings were later scored for somatic signs 
by a blinded trained observer using a validated checklist (Gellert & Holtzman, 1978; 
Schulteis et al., 1994).  Individual categories of withdrawal signs included eye blinks (5-9: 
1 pt; 10+: 2 pts), wet dog shake (1-2: 2 pts; 3+: 4 pts), escape jumps (1-4: 1 pt; 5-9: 2 pts; 
10+: 3 pts) , abdominal constrictions (2 pts/each), swallowing movement (2 pts), facial 
fasciculations (2 pts), abnormal posture (3 pts), ptosis (2 pts), penile grooming (3 pts), 
chromodacryorrhea (5 pts), salivation (7 pts) and diarrhea (2 pts).  The somatic sign score 







 Several animals (see Results for group size of the MOR + NX group during each 
phase of the MSA protocol) were lost to attrition during the course of the protocol due to 
loss of ICSS headcap, loss of stability of ICSS thresholds, failure to acquire MSA, loss of 
catheter patency, health issues, or other problem. Data for these animals are analyzed for 
those phases they completed.  
 
Baseline ICSS measures during acute dependence  
Baseline ICSS thresholds and response latencies did not differ between groups 
during either precipitated or spontaneous withdrawal testing during the acute dependence 
phase (Table S1). 
Locomotor activity  
One-way ANOVA on total distance travelled during the locomotor activity session 
in the MOR + NX and control groups (MOR + SAL, SAL + NX, SAL + SAL) indicated 
no effect of group  (Fig S1A). An additional one-way ANOVA of within-session activity 
in the MOR + NX group indicated a main effect of time (F (3.417, 95.66) = 64.07, p < 
0.0001).  Activity was highest during the first 30 minutes of the 2-hour session (Fig S1B), 
consistent with previous findings from our lab and others (e.g., Study 1; Piazza et al., 1989). 
Distance travelled did not correlate with any subsequent MSA measure (all p ≥ 0.11).  
Comparison of MSA in the MOR + NX and control groups 
Rats in the MOR + NX group and control groups did not differ on most measures 
of MSA. Two-way repeated measures ANOVA on infusion rates between the MOR + NX 





effect of session (F (9, 468) = 2.20, p = 0.02) but no effect of group or interaction between 
group and session (Figure S2A).  Two-way ANOVA on group and FR during demand 
testing showed a significant main effect of FR (F (6, 246) = 152, p < 0.001) and interaction 
between group and FR (F (18, 246) = 2.144, p = 0.005).  but no main effect of group (Figure 
S2B).   The MOR + NX had significantly lower infusions at FR 2 and FR 3 compared to 
the SAL + SAL group (all p < 0.01). However, a one-way ANOVA comparing elasticity 
of demand (α) (i.e., the primary outcome) indicated no significant difference between 
groups (Figure S2C). The MOR + NX and control groups also did not significantly differ 
in three secondary behavioral economic measures: intensity of demand (Q0), maximal 
response output (Omax) and the unit price at which maximal response output occurred (Pmax) 
(Table S2). Additionally, the groups did not differ in infusions during extinction, as a two-
way repeated measures ANOVA revealed a significant overall effect of session (F (10, 
410) = 79.53, p < 0.0001) (Figure S2D) but no effect of group or group x session 
interaction.  Finally, two-way ANOVAs showed a main effect of reinstatement condition 
on reinstatement scores during morphine- and cue-induced reinstatement (F (1.291, 51.65) 
= 28.95, P < 0.0001) and yohimbine- and cue-induced reinstatement (F (1.747, 65.79) = 
22.68, P < 0.0001), with responses significantly elevated during all drug (morphine or 
yohimbine) and/or cue conditions compared to the VEH + CUE control condition (Figure 
S2E-F).  However, there was no significant main effect of group or interaction during either 
morphine- and cue-induced reinstatement testing or yohimbine- and cue-reinstatement 
testing.  





Table S2 shows additional parameters from the exponential demand curve, 
However, these additional measures (Q0, Omax or Pmax) from demand testing did not 
significantly correlate with either ICSS thresholds or somatic withdrawal signs during 
naloxone-precipitated or spontaneous withdrawal in the Mor + NX group during the acute 
dependence phase.  
Late-stage dependence 
 Precipitated withdrawal: ICSS. Baseline ICSS thresholds and response latencies for 
late-stage precipitated withdrawal did not differ between groups (Table S3). Two-way 
ANOVA on ICSS thresholds during precipitated withdrawal revealed a significant main 
effect of group (F (3, 22) = 6.2, p = 0.003), but no significant effect of session or interaction. 
Holm-Sidak’s multiple comparison showed significantly higher ICSS thresholds in the 
MOR + NX group compared to the SAL + SAL control group during all sessions (all t(22) 
≥ 3.71, all p < 0.05) (Figure S3A).  There was no significant effect of group, session, or 
group x session interaction on ICSS latencies during precipitated withdrawal (data not 
shown).  
Spontaneous withdrawal: ICSS. Baseline ICSS thresholds and response latencies 
did not differ between groups (Table S3). ICSS thresholds during hours 2 (agonist effect) 
and hours 6 – 98 (withdrawal period) of spontaneous withdrawal did not differ between the 
two groups receiving MOR (MOR + NX versus MOR + SAL groups) or SAL (SAL + SAL 
versus SAL + NX groups). Data from these groups were therefore combined into a single 
MOR (n = 15) and SAL (n = 5) group. Welch’s corrected t test showed no significant 





groups during the 2-hour session, indicating an absence of effects of MOR itself on ICSS. 
Two-way ANOVA on ICSS thresholds during spontaneous withdrawal 6-98 hours after 
morphine injection revealed no significant main effect of time, group (morphine vs. saline) 
or interaction (Figure S3B). However, comparison of peak ICSS threshold values between 
6 hours and 98 hours (regardless of the time point at which they occurred) differed 
significantly between the morphine (121.7 ± 4.78%) and saline (106.8 ± 2.04%) groups 
(Welch-corrected t(17.54) = 2.85, p = 0.01).  No significant difference in ICSS response 
latencies was observed between groups 2 hours after injection (agonist effect) or 6-98 hours 
after injection (withdrawal effect) (data not shown).  
 Precipitated withdrawal: Somatic signs. One-way ANOVA revealed a significant 
overall difference in somatic signs scores between groups during the 5th session of 
precipitated withdrawal during late stage dependence (F(3, 23) = 4.57, p = 0.01). However, 
Dunnett’s multiple comparison indicated that none of the groups differed significantly from 
the SAL + SAL group (Figure S3C).  
 Spontaneous withdrawal: Somatic signs.  Somatic signs did not differ between the 
two groups receiving MOR or between the two groups receiving SAL. Data from these 
groups were therefore combined into single MOR (n = 15) and SAL (n = 5) conditions, 
respectively.  Total somatic signs in the MOR condition were significantly higher than in 
the SAL condition (Welch-corrected t(21.44) = 2.19, p = 0.04) (Figure S3D). 
Correlations in the MOR + NX group during late-stage dependence 
ICSS thresholds or somatic signs scores during late-stage dependence during 





for a significant correlation between higher composite z-score for ICSS thresholds during 
precipitated withdrawal and higher infusions during extinction (i.e., greater resistance to 
extinction; r = 0.61, p = 0.04). 
 Comparison of withdrawal severity during acute dependence and late-stage 
dependence in rats that completed both phases suggested that these measures were largely 
independent.  Thus, ICSS thresholds during precipitated or spontaneous withdrawal 
during late-stage dependence did not correlate with these same ICSS measures during 
acute dependence (all r: -0.16 ≤ r ≤ -0.04, all p ≥ 0.57).  Somatic signs during 
spontaneous withdrawal correlated significantly between late-stage dependence and acute 
dependence (r = 0.73, p = 0.007), but this correlation was not observed during precipitated 






Mean (±SEM) ICSS thresholds (in µA) and response latencies (in sec) in experimental 















MOR+NX 131.5 ± 13.37 2.62 ± 0.10 132.5 ± 13.99 2.62 ± 0.09 
MOR+SAL 123.3 ± 12.45 2.69 ± 0.20 127.0 ± 12.80 2.59 ± 0.13 
SAL+NX 128.8 ± 15.50 2.50 ± 0.17 133.3 ± 17.90 2.60 ± 0.20 












Exponential demand curve parameters for individual subjects. Note: the parameter k (range 
of consumption) is set to 1.8 log units. 
Subject α Q0 Pmax Omax R2 
MOR + NX      
1 0.0084 4.1 9.4 12.2 0.66 
2 0.0047 11 6.2 21.9 0.81 
3 0.0087 3.6 10.3 11.8 0.64 
4 0.0039 19 4.4 26.4 0.85 
5 0.0034 4.8 19.8 30.3 0.65 
6 0.0011 3.7 79.3 93.5 0.7 
7 0.0025 6.4 20.2 41.2 0.81 
8 0.0052 10 6.2 19.8 0.65 
9 0.0055 3.5 16.8 18.7 0.75 
10 0.0025 4.2 30.7 41.2 0.72 
11 0.0051 5.4 11.7 20.2 0.5 
12 0.0021 7.6 20.2 49 0.89 
13 0.0022 9 16.3 46.8 0.66 
14 0.0053 3 20.3 19.4 0.68 
15 0.00065 5.2 95.5 158.3 0.79 
16 0.0017 10 19 60.5 0.79 
17 0.0079 7.4 5.5 13 0.95 
18 0.0023 7.4 19 44.7 0.79 
19 0.0027 19 6.3 38.1 0.79 
20 0.0012 5.1 52.7 85.7 0.9 
21 0.0028 12 9.6 36.7 0.89 
22 0.0037 8 10.9 27.8 0.84 
23 0.0016 4.6 43.9 64.3 0.95 
24 0.0016 3.6 56 64.3 0.93 
25 0.00078 5.1 81.1 131.9 0.98 
Mean 0.003501 7.31 26.85 47.11 0.78 
SEM 0.000465 0.87 5.22 7.37 0.02 
      
MOR + SAL      
1 0.0027 5 23.9 38.1 0.89 
2 0.0012 6.3 42.7 85.7 0.89 
3 0.0017 4.5 42.2 60.5 0.64 
4 0.0038 4.7 18.1 27.1 0.68 





6 0.0016 8.9 22.7 64.3 0.99 
7 0.0025 5.6 23.1 41.2 0.92 
Mean 0.002049 5.94 32.99 62.77 0.85 
SEM 0.000384 0.58 5.61 12.39 0.05 
 
SAL + NX      
1 0.002 4.3 37.5 51.4 0.96 
2 0.002 5.8 27.8 51.4 0.91 
3 0.0039 13 6.4 26.4 0.96 
4 0.0017 9.3 20.4 60.5 0.57 
5 0.0053 6.7 9.1 19.4 0.9 
6 0.0023 4.4 31.9 44.7 0.73 
Mean 0.002867 7.25 22.18 42.30 0.84 
SEM 0.000582 1.37 5.11 6.53 0.06 
 
SAL + SAL      
1 0.0028 7.7 15 36.7 0.94 
2 0.0016 13 15.5 64.3 0.85 
3 0.0019 10 17 54.1 0.96 
4 0.0046 7.1 9.9 22.4 0.58 
5 0.0015 6.2 34.7 68.6 0.71 
6 0.0018 13 13.8 57.2 0.86 
7 0.0026 5 24.8 39.6 0.96 
8 0.0026 6.8 18.3 39.6 0.94 
Mean 0.002425 8.60 18.63 47.81 0.85 







Mean (±SEM) ICSS thresholds (in µA) and response latencies (in sec) in experimental 
















MOR+NX 134.3 ± 23.12 2.53 ± 0.11 120.6 ± 23.17 2.56 ± 0.09 
MOR+SA
L 
125.1 ± 24.33 2.45 ± 0.12 122.6 ± 24.15 2.43 ± 0.08 
SAL+NX 123.5 ± 17.16 2.52 ± 0.24 113.6 ± 30.19 2.29 ± 0.39 







Mean (±SEM) somatic sign scores in experimental groups during acute dependence naloxone-precipitated withdrawal testing. Each 
individual sign is shown in addition to the total.   Data for escape jumps, salivation and diarrhea are not shown because these signs 


















MOR+NX 0.96±0.13 1.00±0.24 0.57±0.20 1.50±0.17 1.79±0.12 0.43±0.20 0.43±0.16 1.29±0.29 0.36±0.25 8.32±0.62 
MOR+SAL 0.00±0.00 0.22±0.22 0.00±0.00 0.22±0.22 1.11±0.35 0.00±0.00 0.00±0.00 1.67±0.53 0.00±0.00 3.22±0.40 
SAL+NX 1.00±0.15 0.00±0.00 0.20±0.20 0.80±0.33 0.80±0.33 0.60±0.40 0.20±0.20 0.30±0.30 0.00±0.00 3.90±0.81 









Mean (±SEM) somatic sign scores in experimental groups during acute dependence spontaneous withdrawal testing. Each individual 
sign is shown in addition to the total.  Data for escape chromodacryorrhea, jumps, salivation and diarrhea are not shown because these 
















MOR+NX 1.15±0.15 0.46±0.20 0.69±0.35 1.31±0.19 1.54±0.17 0.23±0.16 0.00±0.00 0.81±0.27 6.19±0.77 
MOR+SAL 0.78±0.28 0.67±0.47 0.22±0.22 0.44±0.29 1.78±0.22 0.00±0.00 0.00±0.00 1.67±0.53 5.56±1.17 
SAL+NX 0.67±0.17 0.44±0.29 0.00±0.00 0.22±0.22 0.89±0.35 0.00±0.00 0.22±0.22 1.67±0.53 4.11±0.92 




Figure S1: (A) Mean (± SEM) total distance travelled (in cm) during the 2-hr locomotor 
test in each experimental group; (B) Mean (± SEM) distance traveled in 5-minute blocks 
during locomotor testing in the MOR + NX group. 

















































Figure S2: (A) Mean (± SEM) infusions during MSA acquisition for the MOR + NX and 
control groups. (B) Mean (± SEM) infusions at each FR during demand testing. ** 
Different from SAL + SAL group at that FR, p < 0.01.  (C) Exponential demand curve 
describing morphine consumption as a function of unit price for rats as a group for each of 
the 4 groups. (D) Mean (± SEM) number of infusions during baseline and MSA extinction 
over 10 sessions. (E and F) Mean (± SEM) reinstatement scores during morphine- and cue-






Figure S3: Mean (± SEM) ICSS thresholds (expressed as percent of baseline) during late-
stage naloxone-precipitated withdrawal (A) and spontaneous withdrawal (B). * Different 
compared to SAL + SAL group at that session, p < 0.05. Mean (± SEM) somatic signs in 
groups on the 5th day of late-stage dependence precipitated withdrawal (C) and 26 hours 
after injection during late-stage dependence spontaneous withdrawal (D). *** Significant 
effect of group, p < 0.001.  * Different from SAL condition, p < 0.05.   
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